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1 Introduction 1 
1 Introduction 
1.1 Malignant mesothelioma 
Malignant mesothelioma (MM) is a primary aggressive tumor that affects the 
mesothelium lining of the serosal membranes, such as pleural, peritoneal, and 
pericardial cavities, as well as in the tunica vaginalis testis. This tumor is properly 
referred to as “diffuse malignant mesothelioma”, but is often abbreviated as “malignant 
mesothelioma” Churg et al. 2006. 
 
1.2 Epidemiology 
Before the 1950s, MMs were very uncommon tumors 
Hughes 2005
. With the approach of 
World War II, the demand for asbestos increased in much of the mining, and process 
was taken over by large industrial companies. In 1960, Wagner et al. published a paper 
implicating asbestos exposure in the development of mesothelioma. They noted that 
whereas mesothelioma was rarely encountered in South Africa, in a period of just four 
years, 33 cases were identified by them (32 patients were born on asbestos fields or 
worked near a mine or mill, and only one had no history of asbestos exposure). This 
study provided the strongest evidence to date of a relationship between asbestos and 
mesothelioma. Subsequently, numerous case-control studies confirmed these findings. 
 
There is a long latent period between first exposure to asbestos and diagnosis of MM 
that is seldom less than 15 years and often exceeds 30 years 
Hodgson et al. 2005; Kraus & Müller-
Lux 2004
. In consequence of it, the incidence of MM is expected to continue to increase 
for the next decade. For a large part of the world, data are not available or insufficient, 
due to few mesothelioma registries covering all the national territory. Moreover, 
predictions of the future number of mesothelioma cases have been attempted in different 
countries 
Hodgson et al. 2005; Price & Ware 2004; Leigh et al. 2002; Peto et al. 1999
. 
 
In the United Kingdom (UK), the annual number of mesothelioma deaths has risen 
increasingly rapidly from 153 deaths in 1968 to 1,848 in 2001, and is predicted to peak 
at around 1,950 to 2,450 deaths per year between 2011 and 2015. Between 1968 and 
2050, there will have been approximately 90,000 deaths from MM in the UK; 65,000 of 
which will occur after 2001 
Hodgson et al. 2005
. In the United States of America, it has been 
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estimated, after a peak around 2000-2004 of approximately 2,000 cases, a return to 
background the incidence by 2055. The total projected number of male mesothelioma 
cases in 2003-2054 is approximately 71,000 
Price & Ware 2004
. The expected total number of 
MM cases in Australia from 1945 to 2020 is estimated to be about 18,000 
Leigh et al. 2002
. 
Peto et al. 
1999
 analyzed epidemiologic data from France, the Netherlands, Germany, 
Italy, Switzerland, and Great Britain. They predicted 6,700 deaths caused by MM per 
year for 2015-2019 and a total of 190,000 between 1995 and 2029. These findings show 
that awareness about the danger of asbestos exposure effects was not the same in all 
countries. Despite, varying recent trends in mesothelioma incidence, the disease is 
currently, without doubt, far more common than it was 20 years ago. 
 
1.3 Etiology 
Asbestos is a commercial term used to describe fibrous minerals, categorized into two 
families: serpentine (chrysotile or white asbestos) and amphiboles (e.g. crocidolite or 
blue asbestos, amosite or brown asbestos, tremolite, anthophyllite and actinolite) 
Yarborough 2007; Mark & Kradin 2006
. Known to the ancient Egyptians and mentioned by Pliny as 
“magic mineral”, asbestos was only mined and manufactured in any quantity since 
about the 1890s 
McDonald & McDonald 1996
. It is not combustible, has great tensile strength, 
and has good frictional properties. Asbestos is a good thermal and electrical insulator, 
and is durable, strong and flexible. These properties have led to its use in many 
commercial and domestic settings, including insulation materials, brake pads and 
linings, household products, floor tiles, electric wiring, paints, and cements 
Roach et al. 2002
. 
Amosite and crocidolite are considerably more persistent in tissue than is chrysotile. 
This difference in biopersistence is believed to be the reason that mesothelioma 
incidence rates are much higher in those who used or manufactured products with 
amosite and crocidolite compared to only chrysotile 
McDonald & McDonald 1996
. There is some 
debate about the fiber type-specific ratio of risk: a recent summary proposes that the 
relative risk is 1 for chrysotile, 100 for amosite, and 500 for crocidolite 
Hodgson & Darnton 
2000
. The primary determinant of this difference in carcinogenity between serpentines 
and amphiboles is the physical dimension of the fiber. The length, diameter, and aspect 
ratio are determinants of persistence of fiber within the lung. Short fiber is more easily 
removed by lung macrophages to airways or lymphatics, whereas fibers in the 1m to 
20m range are retained Hughes 2005. Fiber dimensions are also thought to be important for 
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MM induction, so short-length fibers have little carcinogenic activity in comparison to 
long-length fiber (>5m in length and especially > 8-10m in length) Galateau-Salle et al. 2006. 
 
The long-term social and medical costs resulting from asbestos exposure have resulted 
in the European Ban Asbestos Movement that pushed a decision from the European 
Union to prohibit the import, manufacture, marketing, and use of asbestos after January 
1, 2005 
Comission directive 1999/77/EC 1999
. The estimates on the basis of the past consumption, 
predict that the asbestos-related morbidity continues in an epidemic scale until 2070 in 
these countries which have banned the use of asbestos. In the 1980s and 1990s, the use 
and consumption of asbestos has increasingly moved to the developing countries. These 
will experience the peak of asbestos-related mortality later than the industrialized 
countries, i.e., in 2030-2050. However, the epidemic will continue long time after the 
peak 
Rantanen 2003
. Canada is the only developed country that produces, almost entirely for 
export, significant quantities of asbestos fibers 
Harris & Kahwa 2003
. The largest producer is 
Russia, representing 39.5% of the total asbestos mined worldwide, followed by 
Kazakhstan (15.8%), China (15.4%) and Brazil (11.1%) 
Giannasi 2007
. Thailand, India, 
South Korea and Iran are major importers of asbestos 
Harris & Kahwa 2003
. 
 
The causal relationship between asbestos exposure and MM is well known, but not all 
patients with MM have a history of asbestos exposure. It has been proposed that Simian 
virus 40 (SV40) could be a possible etiological factor for MM, based on the detection of 
SV40-DNA sequences in samples from MM patients. The disease may also be causally 
linked with poliomyelitis vaccine contaminated with SV40, which was administrated to 
millions of people in Europe and the USA between 1955 and 1963 
Churg et al. 2006
. It has 
been hypothesized that SV40 could act as coactivator of asbestos in the carcinogenic 
process. At present, therefore, it remains unclear whether a causal association exists 
between SV40 and elevated rates of mesothelioma 
Gazdar et al. 2002
. A malignant 
mesothelioma epidemic occurs in three villages in Cappadocia, Turkey: Tuzkoy, Karain 
and “Old” Sarihidir. This epidemic has been linked to erionite exposure. Erionite is a 
fibrous zeolite mineral; morphological similar to amphibole form of asbestos, formed 
by alteration of volcanic rocks 
Dogan et al. 2006
. There is a hypothesis that a MM-susceptive 
gene can genetically be altered in Cappadocian families 
Carbone & Bedrossian 2006
. Sporadic 
cases of mesothelioma occurring after radiotherapy have been reported, suggesting that 
ionizing radiation may also be a risk factor for MM 
Cavazza et al. 1996
.  
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1.4 Pathogenesis 
Four plausible explanations have been proposed to how asbestos causes malignant 
change in mesothelial cells: first, there is pleural irritation. The fibers can penetrate the 
lung, repeatedly scratching the mesothelial surface and causing prolonged cycles of 
damage, repair, and local inflammation. This process can lead to scarring (plaques) or 
cancer (mesothelioma). Second is interference with mitosis. Fibers can sever and pierce 
the mitotic spindle, disrupting mitosis, which has the potential leading to aneuploidy 
and other forms of chromosome damage that characterize mesothelioma. Generation of 
toxic oxygen radicals is a third explanation. Asbestos-induced cell damage is mediated 
to some extent by iron-related reactive oxygen species (ROS), which induce DNA 
damage and strand breaks
 Robinson et al. 2005
. And fourth is persistent kinase-mediated 
signaling. Asbestos-induced DNA damage stimulates a signal transduction cascade. 
Asbestos can activate mitogen-activated protein (MAP)-kinase signaling pathways 
through the epithelial growth factor (EGF) receptor. Several of the transcription factors 
induced in this pathway, such as NFkB, AP1 (C-fos, C-Jun), and C-myc, are found 
highly expressed in mesothelioma 
Galateau-Salle et al. 2006
. 
 
1.5 Clinical features 
The median age for presentation with MM is around 60 years. Women with peritoneal 
mesotheliomas have a wide age range, with a much larger proportion seen in young 
women. Malignant mesotheliomas occasionally occur in children and teenagers 
Churg et al. 
2006
. 80% of patients with pleural MM are male and commonly present with an 
unexplained pleural effusion associated with breathlessness and chest pain, sometimes 
accompanied by weight loss, fatigue, cough or fever 
Robinson & Lake 2005
. On rare occasions, 
there are no symptoms and the tumor is discovered though the incidental observation of 
a pleural effusion or pleural thickening on chest X ray. A few patients have presented 
with pneumothorax, metastases to nodes, and even multiple small intrapulmonary 
metastases mimicking military tuberculosis on chest X ray in the absence of obvious 
pleural disease. As a general rule, however, patients who present metastatic disease are 
more likely to have an underlying carcinoma than a mesothelioma 
Churg et al. 2006
. CT 
scans might also reveal MM by identifying diffuse irregular pleural thickening. PET 
scanning can help to distinguish benign from malignant pleural masses and to detect 
extrathoracic deposits, particularly lymph-node involvement 
Tsiouris & Walesby 2007
. 
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1.6 Histological classification 
There are four histological subtypes of MM. Epithelial tumors constitute 40% of MMs 
and are associated with pleural effusions and a slightly better prognosis; sarcomatoid 
tumors comprise 20% of MMs and are termed “dry” mesotheliomas; mixed tumors 
constitute 35% of MMs; and the undifferentiated subtype is rarest, comprising 5% of 
MMs. Proposed staging methods are not widely accepted, and staging systems are 
currently of minimal use for treatment of MM as there are few surgical-pathological 
data available from carefully staged patients with MM 
Tsiouris & Walesby 2007
. 
 
There is no universally accepted method of staging MMs, in part because the prognosis 
has been so uniformly dire that staging seems to serve little purpose. The most detailed 
staging system is that proposed by the International Mesothelioma Interest Group 
(IMIG), but other, simpler, systems are also currently employed 
Churg et al. 2006
. According 
to IMIG staging system, T1 indicates tumor that involves ipsilateral parietal pleura, 
without (T1a) or with (T1b) focal involvement of visceral pleura. T2 indicates tumor 
that involves any of the ipsilateral pleural surfaces, with at least one of the following: 
confluent visceral pleural tumor (including fissure), invasion of diaphragmatic muscle, 
or invasion of lung parenchyma 
Van Schil 2005
. The aim of cytology is to identify this tumor 
in these stages. 
 
1.7 Effusions 
Effusion is the accumulation of fluid in a body cavity, which has a variety of benign and 
malignant etiologies. The most common benign etiologies are infections (bacterial, 
fungal, viral, and parasitic), congestive heart failure, pulmonary embolism, myocardial 
infarction, cirrhosis, nephrotic syndrome, collagen vascular disease, pancreatitis, and 
trauma 
Koss & Melamed 2006, Pereira et al. 2006
. Most benign effusions show mostly non-specific 
findings, consisting of neutrophils, lymphocytes, macrophages, red blood cells, fibrin, 
reactive mesothelial cells, and/or occasionally eosinophils 
Gray & McKee 2003
. Perhaps the 
most important cytologic feature of benign effusions is the range of appearance of 
reactive mesothelial cells. Reactive mesothelial cells can occasionally appear very 
atypical and therefore serve as a major pitfall for a false positive diagnosis of 
malignancy 
Pereira et al. 2006
. 
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Although most patients with a malignant effusion have a known history, a tumor cell-
positive effusion may be the first indication of an unsuspected malignancy 
Churg et al. 2006; 
Pereira et al. 2006; Gray & McKee 2003; Motherby et al. 1999c
. In patients without a known primary site, 
clinical features such as age, sex, and the serous cavity involved can help to narrow 
down the diagnostic possibilities 
Pereira et al. 2006
.  
 
The most common primary sites or tumor types for malignant pleural effusions in male 
patients are in descending order of frequency lung, lymphoma/leukemia, gastrointestinal 
(GI) tract, and genitourinary tract 
Gray & McKee 2003; DeMay 1996
. In female patients with a 
malignant pleural effusion, the most common location or tumor types reported in 
descending frequency are breast, female genital tract, lung, lymphoma/leukemia, and GI 
tract, but lung carcinoma has become the first or second most common primary site
 
Pereira et al. 2006; DeMay 1996
. In peritoneal effusions, the most common primary sites or tumor 
types in men in descending frequency are GI-tract, pancreas, prostate, and 
hematopoietic malignances. In adult female, the most common primary sites or tumor 
types are ovaries, breasts, uterus, GI-tract, and hematopoietic malignances. The most 
common malignancies or tumor types in pericardial effusions in adults are lung, breast, 
lymphoma/leukemia, and mesothelioma 
DeMay 1996
. 
 
The cytological diagnoses on serous effusions are usually made by routine 
cytomorphology with high accuracy, allowing treatment decisions. It is one of the most 
specific, time- and cost-effective methods with high clinical relevance. Motherby et al. 
2002
 reported as an average from the literature a specificity about 97% and sensitivity of 
about 58% of conventional cytology for the detection of malignant cells in effusions, so 
that without adjuvant methods 3% of cytological diagnoses in effusions are false-
positive and 42% false-negative. False-positive results may occur due to chronic 
irritations of different circumstances 
Fiegl et al. 2004
. The false-negative results mean that 
tumors that had spread to the serous membranes are cytologically not detected in 
effusions. This is caused by sampling errors in about 72% of effusions and by screening 
errors in about 28% 
Motherby et al. 1999c
. Those data are mainly caused by differences in the 
experience of the investigators and in the quality of preparations. Even experienced 
investigators, however, are not always able to distinguish unequivocally between 
reactive, atypical, or beyond doubt malignant cells, especially in effusions with few 
degenerate tumor cells. 
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The diagnosis of malignant mesothelioma in serous effusion is difficult and represents 
one of the classic diagnostic challenges of cytopathology. The morphological features 
are not always reliable for the differentiation between neoplastic and non-neoplastic 
mesothelial cells or between mesothelioma cells and those from metastatic 
adenocarcinomas 
Bedrossian 1998
. Early and precise diagnosis of MM in effusion is crucial 
for patient management and may avoid unnecessary invasive diagnostic procedures. 
Recent advances in therapy for patients with MM can result in an improved outcome if 
they are applied to Stage I disease 
Illei et al. 2003a
. Furthermore, from a legal viewpoint, 
compensation claims from workers occupationally exposed to asbestos demands an 
accurate and early diagnosis of MM. Cytological atypia is an unreliable criterion for 
MM because it can be monotonous and deceptively bland. For example: although 
prominent nucleoli are characteristic for MM, reactive mesothelial cells may show 
prominent nucleoli and mitosis, raising the suspicion for malignancy in a benign process 
Gray & McKee 2003
. 
 
To improve the diagnostic sensitivity, various additional approaches have been 
proposed including DNA-image cytometry (DNA-ICM), immunocytochemistry and 
silver staining of nucleolar organizer regions-associated proteins (AgNORs). 
 
1.8 Adjuvant methods 
1.8.1 DNA-image cytometry (DNA-ICM) 
DNA-ICM is a quantitative adjuvant method, which is more objective than traditional 
subjective methods, to establish the diagnosis of malignancy in different preneoplastic 
lesions and for grading of tumor malignancy of manifest cancers. Four international 
consensus reports of the European Society of Analytical Cellular Pathology (ESACP) 
on standardized diagnostic DNA-ICM provided guidelines and performance standards 
for diagnostic DNA measurements, definitions of terms and algorithms for diagnostic 
data interpretation 
Böcking et al. 1995; Haroske et al. 1998; Giroud et al. 1998; Haroske et al. 2001
.  
 
Chromosomal aneuploidy is defined as numeric and/or structural aberrations. It is an 
early key event in tumorigenesis caused by genetic instability 
Haroske et al. 2001; Böcking 1995
. 
The cytometric equivalent of chromosomal aneuploidy, DNA aneuploidy, serves as a 
marker of neoplasia by assessing large-scale genomic alterations resulting from genetic 
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instability 
Haroske et al. 2001
. DNA-ICM is capable of monitoring the effect of cytogenetic 
tumor progression on nuclear DNA content.  
 
The hypothesis that chromosomal aneuploidy itself may be a cause of cancer was 
proposed first by Boveri at the beginning of the 20
th
 century 
Boveri 1914
. During recent 
decades, this hypothesis was ignored, because most efforts were centered on the 
hypothesis of somatic gene mutations. Recently, it is observed that the correlation 
between aneuploidy and malignancy is strong and is evident in almost all solid 
malignancies. Therefore, the aneuploidy-malignancy correlation explains both the 
growing list of nonmutagenic carcinogens and why most human oncogenes cannot turn 
human cells into cancer cells 
Duesberg 2007
.  
 
The nuclear DNA content cannot be measured directly by cytometry. After quantitative 
DNA staining, the nuclear IOD is the cytometric equivalent of its DNA content in 
DNA-ICM. Therefore, the DNA content is expressed in a c scale, in which 1c is half of 
the mean nuclear content of cells from a normal (not pathologic), diploid population in 
G0/G1 cell cycle phase. DNA ploidy is the expression of the typical large-scale 
genomic status of a cell population. The DNA content of a cell is changed regularly 
throughout the cell cycle 
Haroske et al. 2001
. The basic objective of DNA-ICM is to identify 
DNA stemlines outside the euploid (diploid, tetraploid, or octaploid) regions as 
abnormal (or aneuploid) at a defined statistical level of significance. Because most 
interpretation of DNA measurement is population based, the results usually are 
displayed as DNA histograms 
Böcking 1995
. 
 
1.8.2 Immunocytochemistry 
Immunocytochemistry is a method for localizing specific antigens in cells or tissues 
(immunohistochemistry) based on antigen-antibody recognition; it seeks to exploit the 
specificity provided by the binding of an antibody with its antigen at a light microscopic 
level 
Dabbs 2006
. An antibody is a molecule that has the property of combining specifically 
with a second molecule, termed the antigen. Further, the production of antibody an 
animal is induced specifically by the presence of antigen; this forms part of the basic 
immune response. Antibodies are immunoglobulin molecules consisting of two basis 
unit: a pair of light chains (either a kappa or a lambda pair) and a pair of heavy chains 
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(gamma, alpha, mu, delta, or epsilon) bound together by disulfide linkages 
Taylor & Cote 
2006; Dabbs 2006
.  
 
Of the various ancillary techniques that have been used in the differential diagnosis of 
mesotheliomas, immunohistochemistry has been recognized as having the most 
practical utility. A specific tumor marker for mesotheliomas has not yet been 
recognized; therefore, the immunohistochemical diagnosis of this tumor largely depends 
on the use of panels of markers that are frequently expressed in mesotheliomas (positive 
mesothelioma marker) combined with those that are commonly expressed in 
adenocarcinomas (negative mesothelioma marker) 
Ordonez 2007
.  
 
1.8.3 Silver staining of nucleolar organizer regions-associated proteins (AgNORs) 
Nucleolar organizer regions (NOR) are large rDNA loops localized in the nucleolus, on 
satellite areas of the p-arm of acrocentric chromosomes 13, 14, 15, 21 and 22. They are 
responsible for the transcription of rRNA 
Derenzini 2000
. Beside these regions lie non-
histone acid proteins (nucleolin, RNA polymerase I) which are selectively silver-stained 
and are the labeled AgNORs 
Sirri et al. 2000
. These complexes are visualized as smaller or 
larger brownish-black dots and represent transcriptively active nucleolar parts 
Rüschoff 
1992
. The transformation from normal to malignant cell is characterized by an increased 
protein synthesis, resulting in an increase in number and area of nucleoli. Therefore, 
AgNOR can be considered as a marker of cell proliferation, and also could help in 
distinguishing benign from malignant lesions 
Derenzini 2000; Sirri et al. 2000
. 
 
A definitive standardization of AgNOR staining and qualification has not yet been 
achieved, and the AgNOR scores reported by different authors for the same tumor types 
are scarcely comparable. The genesis of these divergent data must be related to: the use 
of different methodological applications of NOR silver-staining, and the use of different 
procedures for AgNOR protein quantification 
Trere 2000
.  
In cytologic preparations, the AgNOR technique has not been used frequently so far. 
However, some studies have demonstrated good results with air dried and ethanol-fixed 
smears 
Palaoro et al. 2007; Mohanty et al. 2003; Pomjanski et al. 2001; Rocher et al. 2000
. Quantification of 
AgNORs in nucleoli in cytological specimens has the important advantage relating 
results to whole individual nuclei avoiding problems arising from the evaluation of 
nuclear sections 
Pomjanski et al. 2001
. 
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It is observed that malignant cells frequently exhibit a greater AgNOR protein amount 
as compared with the corresponding benign or normal cells 
Derenzini 2000
. Pomjanski et al. 
2001
 counted individual dots (satellites) and dots aggregation or partly disaggregated 
nuclei considered as one structures (clusters) together and found thresholds of 2.5 
AgNOR dots as satellites and 4.5 as satellites and clusters together. They obtained 
97.5% corrected rate of tumor cells identification in serous effusions. 
 
1.8.4 Fluorescence in situ hybridization (FISH) 
Fluorescence in situ hybridization (FISH) is a powerful molecular technology which 
permits the localization of particular DNA sequences to a specific chromosome or 
chromosomal region. FISH depends on the formation of a hybrid between a 
fluorescently-labeled DNA probe and its target chromosomal DNA. The methodology 
involves denaturation of the probe and target sequences, reannealing of the probe and 
target and visualization of resultant hybrid by fluorescence microscopy 
Koss & Melamed 2006
.  
 
The use of fluorescent in situ hybridization for diagnostic purposes has increased 
significantly in the last few years, primarily because it provides in situ information 
about genetic or chromosomal changes and because it is applicable to archival and fresh 
material 
Illei et al. 2003a
. In cancer research and diagnosis, interphase cytogenetics by FISH 
is used to detect numerical chromosome changes and structural aberrations, e.g., 
translocations, deletions, or amplifications 
Oliveira & French 2005
. The major advantage of 
interphase cytogenetics is the possibility of examining chromosomal aberrations among 
morphologically different cells or cell groups that may be evident in an individual tumor 
sample 
Fiegl 2005
. Cytological material is better suited for FISH than paraffin embedded 
tissue sections, because sectioned nuclei loose part of their genetic material. Therefore 
FISH-results are difficult to interpret in histology 
Illei et al. 2003a
. 
 
Cytogenetic and molecular studies have identified several frequent genetic alterations in 
mesothelioma
 Sandberg & Bridge 2001
, of which one of the most common is homozygous 
deletion of the 9p21 locus within a cluster of genes (CDKN2B, CDKN2A, and MTAP) 
Illei et al. 2003a; Illei et al. 2003b; Hirao et al. 2002; Björkqvist et al. 1997; Xiao et al. 1995; Cheng et al. 1994
. CDKN2A 
encodes two important cell cycle regulatory proteins, the p16 protein and, in an 
alternative reading frame, the p14ARF protein. P16, a cyclin-dependent kinase 
inhibitor, acts through CDK4/CDK6 and blocks the phosphorylation of the RB protein, 
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and p14ARF binds MDM2, thus preventing the latter from binding p53 and targeting it 
for degradation 
Stahel 2006; Illei et al. 2003b
 (Figure 1). 
 
 
 
 
Figure 1: 9p21 deletions observed in malignant mesothelioma Stahel 2006. AMP: adenine monophosphate; 
MTA: methylthioadenosine; MTAP: methylthioadenosine phosphorylase; MTR-1-P: methylthioribose-1-
phosphate. 
 
 
The detection of homozygous CDKN2A deletion by FISH would have been helpful in 
confirming a diagnosis of mesothelioma over reactive mesothelial cells 
Illei et al. 2003a
. 
However, this deletion is found in a wide spectrum of tumors including melanoma, 
pancreatic adenocarcinoma, glioblastoma, certain leukemias, non-small cell lung cancer 
and bladder carcinoma 
Kim & Sharpless 2006
. 
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2 Material and Methods 
2.1 Patient selection 
Between March 2005 and May 2007, 48 body cavity effusion specimens from 47 
patients were positive or suspicious for malignant mesothelioma after routine 
investigation by conventional cytology, DNA-image cytometry, immunocytochemistry 
and AgNOR-analysis in the Institute of Cytopathology of the Heinrich-Heine 
University. The patients were from the University Hospital of Düsseldorf as well as 
from hospitals of the surrounding area. The cases were taken from the routine files 
consecutively according to cytological diagnoses of mesothelioma or suspicious. A total 
of 33 effusions were analyzed in the current study (28 men and 5 women; mean age, 70 
years, range, 47-88 years), in which 6 were cytologically suspicious and 27 positive for 
mesothelioma (Table 1). 15 cases were excluded because FISH could not be performed 
due to a small number of atypical cells (10), to the presence of atypical cells in clusters 
only (2), or unsuitable hybridization (3). 
 
Table 1: Summary of cytological diagnosis of body cavity effusions 
Cytological diagnosis Pleural 
effusion 
Peritoneal 
effusion 
Total 
Reactive effusion 36 4 40 
Suspicious for malignant mesothelioma 5 1 6 
Positive for malignant mesothelioma 25 2 27 
Metastatic carcinomas 20 11 31 
Total 86 18 104 
 
 
In addition to the mesotheliomas cases, effusions from 31 metastatic carcinomas and 40 
with reactive mesothelial cells were obtained from the Institute of Cytopathology of the 
Heinrich-Heine University for subsequent applications of adjuvant methods such as 
DNA-ICM, immunocytochemistry, AgNOR-analysis and FISH. Cases with metastatic 
carcinoma (7 men and 24 women; mean age, 66 years, range, 43-87 years) were 
opportunistically obtained, between October 2005 and April 2007, from patients with a 
previous diagnosis of cancer. Cases with reactive mesothelial (24 men and 16 women; 
mean age, 67 years, range, 21-91 years) were also opportunistically obtained, between 
March 2005 and May 2007. The slides must contain a sufficient number of cells for the 
application of adjuvant methods. The cytological diagnoses are summarized in Table 1.  
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2.2  Effusion specimens procedure 
The specimens contained 10-100 ml of effusions each. Native materials were 
centrifuged at 400g for five minutes (Rotina 46 centrifuge, Hettich GmbH, Tuttlingen). 
The supernatant was discarded. One to two drops of sediment were placed on a slide by 
means of a disposable glass pipette. A second clean slide was placed over the sediment 
and allowed it to spread evenly between the two slides. Eight slides were processed. 
Three of these were air-dried and stained according to May-Grünwald-Giemsa (MGG). 
Five further slides were immediately fixed in Delaunay´s fixative (500ml 99.5% ethanol 
+ 500ml acetone extra pure (Merck, Darmstadt, Nr: 1.00013.2500) + ten drops of 1M 
Trichloroacetic acid (Merck, Darmstadt, Nr: 1.00807.0100)) and stained according to 
Papanicolaou (PAP). Two of the stained MGG slides were used for such adjuvant 
methods as DNA-image cytometry (DNA-ICM) and AgNOR-analysis and the stained 
Papanicolaou slides were used for immunocytochemistry (Figure 2). 
 
 
 
Figure 2: Flow chart illustrating the multimodal analysis of serous effusion. MGG: May-Grünwald-
Giemsa; PAP: Papanicolaou; DNA-ICM: DNA-image cytometry; AgNORs: silver staining of nucleolar 
organizer regions-associated proteins; ICC: immunocytochemistry. 
 
2.2.1 MGG staining  
Slides were stained in May-Grünwald solution (Merck, Darmstadt, Nr: 1.01424.2500) 
for five minutes and washed two times in buffered distilled water (pH 6.8) for a short 
time. Slides were then stained in Giemsa solution (Merck, Darmstadt, Nr: 
1.09204.0500) for 15 minutes and washed two times in buffered distilled water (pH 6.8) 
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for a short time. Following slides were dried and mounted with Entellan (Merck, 
Darmstadt, Nr: 1.07961.0500). 
 
2.2.2 Papanicolaou staining 
Slides were rehydrated in decreasing ethanol concentrations (96%, 80%, 70%, and 
50%), washed in distilled water for one minute, stained in Harris’hematoxylin-1a 
solution (Merck, Darmstadt, Nr: 1.09253.2500) for two minutes, washed in tap water 
for three minutes and immersed in NH2OH for one minute. Slides were then dehydrated 
in increasing ethanol concentrations (50%, 70%, 80% and 96%), stained in Orange-II-
2b solution (Merck, Darmstadt, Nr: 1.06887.2500) for two minutes, immersed two 
times in 96% ethanol for one minute each, stained in Polychromatic-3b solution (Merck, 
Darmstadt, Nr: 1.09272.2500) for two minutes, immersed two times in 96% ethanol for 
one minute each, and immersed 100% ethanol for two minutes, ethanol/xylene (1:1) for 
two minutes and three times in xylene for one minute each. Following slides were 
mounted with Entellan (Merck, Darmstadt, Nr: 1.07961.0500). 
 
2.3 Cytological diagnosis 
Specimens were routinely evaluated according to generally accepted diagnostic criteria 
Koss & Melamed 2006; Gray & McKee 2003; Böcking 1998 
by two experienced cytopathologists (N.P. and 
A.B.). The following diagnostic criteria were used for the identification of malignant 
cells: increased occurrence of cell complexes of more than four cells, eccentric location 
of nuclei, increased nuclear/cytoplasmic ratio, marked anisonucleosis, nuclear 
pleomorphism, nuclear overlap und molding, irregularity of nuclear membrane, 
hyperchromasia, irregularity of chromatin distribution, and coarsely granular chromatin. 
The morphologic characteristics to differentiate reactive mesothelial cells from 
malignant mesothelioma and adenocarcinoma are summarized in Table 2 
Pereira et al. 2006
. 
The following categories of cytologic diagnoses suggested by Böcking & Freudenberg 
1998 were used: “insufficient” for specimens without any or with exclusively autolytic or 
necrotic cells, “negative” for inconspicuous, reactive or inflammatory cellular changes, 
“doubtful” in cases with atypical cellular activation or degeneration, “suspicious” if 
only sparse abnormal cells were seen or the diagnostic criteria for malignancy were only 
vague and “positive” for effusions containing unequivocal malignant cells. 
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Table 2: Morphologic characteristics of reactive mesothelial cells, malignant mesothelioma and 
metastatic adenocarcinoma 
 Reactive Mesothelial 
Cells 
Malignant 
Mesothelioma 
Metastatic 
Adenocarcinoma 
Population Single Single Usually dual 
Clusters Few Many Varying from few to many 
Clusters size Small, < 12 cells Very large, > 50 cells Large, > 12 cells 
Border of clusters Scalloped, knobby Scalloped, knobby Smooth 
Windows Common Common Unusual 
Cytoplasm Two-tone staining: 
endo-ectoplasmic 
demarcation 
Two-tone staining: 
endo-ectoplasmic 
demarcation 
Delicate, homogeneous, 
uniform staining 
“Lacy skirt” Present Present Unusual 
Signet ring May be present in 
degenerated cells, but 
nucleus not distorted 
May be present in 
degenerated cells, but 
nucleus not distorted 
May be present. The 
vacuole pushes and distorts 
the nucleus 
Mitotic features May be present May be present May be present 
N/C ratio Mostly low Varies from low to 
high 
Mostly high 
Nucleus position Usually central or 
paracentral 
Usually central or 
paracentral 
Usually eccentric 
Nuclear shape Round or oval Less pleomorphic than 
adenocarcinoma 
Irregular 
Nuclear membrane Thin, smooth Thick Thick 
Multinucleation Common Common Common 
Chromatin Delicate and pale, but 
can be clumped and 
dark 
Hyperchromatic Coarse 
Nucleoli Can be large Large Large 
 
2.4 DNA-image cytometry (DNA-ICM) 
2.4.1 Feulgen staining 
Routine MGG-stained smears from effusions were uncovered in xylene. All specimens 
were Feulgen stained in a temperature-controlled staining machine with Schiff’s reagent 
Chatelain et al. 1989
. After rehydration in decreasing ethanol concentrations (100% and 96%) 
for five minutes each, re-fixation in buffered 10% formalin for 50 minutes and washed 
two times in distilled water for ten und five minutes respectively, 5N HCl (Merck, 
Darmstadt, Nr: 1.09911.0001) for acid hydrolysis was applied at 27.5ºC for 60 minutes, 
followed by washing three times in distilled water for two minutes, staining in Schiff’s 
reagent (Merck, Darmstadt, Nr: 1.09033.0500) for another sixty minutes at room 
temperature (RT), rinsing in SO2 water and dehydration at increasing ethanol 
concentrations (70%, 96%, 100%) for three minutes each. The slides were then 
immersed in xylene for 15 minutes and covered with Entellan (Merck, Darmstadt, Nr: 
1.07961.0500). 
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2.4.2 Measurement 
Measurements of nuclear DNA contents were performed using a computer based image 
analysis system consisting of a Zeiss Axioplan 2 microscope (Zeiss, Jena, Germany) 
(Figure 3) with a 40x objective (numeric aperture, 0.75; Köhler illumination) and a 
charge-coupled device black-and-white video camera with 572 lines of resolution 
(VariCam CCIR; PCO Computer Optics, Kehlheim, Germany) 
Böcking 1995
. The software 
package used in the current study was the AutoCyte QUIC-DNA-Workstation 
(AutoCyte Inc., Burlington, NC), which provides shading and glare correction. The 
latter was performed at a rate of 2.2%. In each case at least 30 lymphocytes were 
measured as internal reference; a correction factor of 1.00 was used to obtain the normal 
2c value. The coefficient of variation of reference cells was always below 5% 
Haroske et al. 
1998
. A minimum of 300 chosen nuclei of interest (reactive mesothelial cells or atypical 
mesothelial cells or carcinoma cells) were randomly measured per specimen. All 
technical instruments and all software used in the study met the standard requirements 
of the consensus reports of the European Society for Analytical Cellular Pathology 
(ESACP) 
Haroske et al. 2001; Haroske et al. 1998; Giroud et al. 1998; Böcking et al. 1995
. 
 
 
Figure 3: Zeiss Axioplan 2 Microscope with a charge-coupled device black-and-white video camera and 
the AutoCyte QUIC-DNA-Workstation software. 
 
A number of parameters were assessed for diagnostic interpretation 
Haroske et al. 2001; Haroske 
et al. 1998; Giroud et al. 1998; Böcking et al. 1995
. DNA stemline is the G0/G1 cell phase fraction of a 
proliferating cell population (with a first peak and a second doubling peak or with 
nuclei in the doubling region). DNA stemline ploidy was defined as the modal value of a 
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DNA stemline in c units (c = DNA content). DNA stemline aneuploidy was assumed if 
the modal value of a stemline was <1.80c or >2.20c and <3.60c or >4.40c. Rare DNA 
events included the 9cEEs, which were defined as the number of cells with a DNA 
content >9c. Single-cell aneuploidy was diagnosed when at least one cell per slide had 
DNA content >9c (9cEE > 1) 
Haroske et al. 1998
. As Biesterfeld et al. 
1994
 found, cells 
between 5c and 8c occur in 6.5% of mesothelial cell samples (serous effusion); without 
tumor cells the threshold for the detection of abnormal, rare cells was to be set at 9c and 
not at 5c 
Motherby et al. 1999a; Motherby et al. 1999b; Motherby et al. 1998a; Motherby et al. 1998b
. 
 
2.5 Immunocytochemistry 
2.5.1 ABC method 
Immunocytochemistry was performed on routine slides previously fixed according to 
Delaunay and stained according to Papanicolaou. On these slides, cells of interest were 
marked by felt-tip pen. Coverslips were then removed in xylene at room temperature 
(RT). The coverslips fell off within 24 hours. If there were not enough slides from a 
patient to apply different antibodies, the slides were divided into two or three regions 
using a DakoPen (Dako, Glostrup, Denmark, Nr: S2002). Thus more than one antibody 
could be applied simultaneously on the same slide. The avidin-biotin complex method 
(ABC) was applied for the visualization of immunologic reactions. The incubations 
were carried out in a horizontal position of the slides in a humidified chamber. All other 
steps were carried out in an upright position of slides in cuvettes. Endogenous 
peroxidase activity was stopped by incubation with 1 ml H2O2 (30% Perhydrol in 100 
ml methanol (Merck, Darmstadt, Nr: 1.07209.0250, Nr: 1.06008.2500) for 30 minutes 
at RT. After rinsing the slides manually three times in phosphate buffered saline (PBS), 
they were then placed twice in PBS at RT for ten minutes each. They were then 
incubated in normal (horse) serum (for mouse antibodies) -225µl: 15 ml distilled water- 
(Vector Laboratories, Burlingame, CA, USA, Nr: S-2000) for 20 minutes at RT. Letting 
the residual liquid drip off the slide by slanting, the slides were incubated at 25ºC 
overnight with commercially available monoclonal primary antibodies (Table 3). The 
slides were then rinsed twice in 0.5 M. TRIS (tris(hydroxymethyl)aminomethan) 
pH=7.6 in PBS 1:10 for five minutes at RT each. This was followed by incubation with 
biotinylated link antibody (Vector Laboratories, Burlingame, CA, USA, Nr: BA-2000) 
for 30 minutes at RT and once again the slides were rinsed twice in 0.5 M. TRIS in PBS 
1:10 for five minutes at RT. The slides were then incubated with the ABC-Elite-
2 Materials and Methods  18 
Standard (Vectastain Laboratories, Burlingame, CA, USA, Nr: PK-6100) for further 30 
minutes at RT and once again rinsed twice in 0.5 M TRIS (Merck, Darmstadt, Nr: 
1.08382.0500) in PBS 1:10 for five minutes at RT. The substrate chromagen reagent 
AEC (3-amino-9-ethylcarbazole) (Sigma-Aldrich Chemical, Taufkirchen, Nr: A5754) 
was then applied for 40 minutes at RT followed by rinsing twice in sterile distilled 
water for five minutes at RT each. Counterstaining was performed with Mayer´s 
Hematoxylin for one minute at RT, rinsed under tap water and cover-slipped in Aquatex 
(water-based mounting medium, Merck, Darmstadt, Nr: 1.08562.0050). 
 
Apart from the fact that all of our antibodies were originally tested with tumor-positive 
and -negative effusions, we did not apply positive and negative controls on separated 
slides routinely due to scarcity of smears. Normal macrophages, lymphocytes and 
granulocytes were usually used for internal negative control. 
 
2.5.2 Antibodies 
Table 3 provides the characteristics, dilutions, pre-treatments and providers of 
antibodies used. We applied BerEP4 and calretinin in all effusion from MM, metastatic 
carcinoma and with reactive mesothelial cells. When there were enough slides in 
morphologic suspicious cases of malignant mesothelioma we also applied EMA, 
mesothelin and WT-1.  
 
Table 3: Antibodies, clones, dilutions, pre-treatments and providers 
Antibody Clone Dilution Pre-treatment Provider 
BerEP4 BerEP4(1) 1:200 None Dako Corporation 
Calretinin DAK-Calret 1 1:200 None Dako Corporation 
EMA E-29 1:1600 None Dako Corporation 
Mesothelin NCL Meso 1:200 None Novocastra 
WT-1 6F-H2 1:200 None Dako Corporation 
BerEP4: surface and cytoplasmic glycoprotein; EMA: epithelial membrane antigen; WT-1: Wilms’ tumor 
protein 1 
 
2.5.3 Microscopic evaluation 
Antibody reactions were evaluated per case, without knowledge of patient follow-up in 
order to avoid any bias in decision making. To exclude false positive results due to 
artificial or unspecific staining, cases that stained ≤10% of cells or showed diffuse weak 
staining were considered negative and others positive. Staining intensity per cell was 
not evaluated because it depends too much on the different variables of the staining 
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process. Prevalence of staining was evaluated for each antibody in reactive mesothelial 
cells and in the respective abnormal cell population in each effusion. The results were 
given as percentage per slide. 
 
2.6 Silver staining of nucleolar organizer regions-associated proteins 
(AgNORs) 
2.6.1 Silver staining 
Silver staining was performed according to the one-step method of Ploton et al. 
1986
 
Crocker et al. 
1989
 and Rüschoff 
1992
 with some modifications. Routine MGG-stained 
smears from effusions were uncovered in xylene. For AgNOR staining the smears were 
placed in xylene for five minutes, then fixed for five minutes in absolute ethanol and 
five minutes in a mixture of 100 ml 96% ethanol with five drops acetic acid and then 
rehydrated in decreasing ethanol concentrations (96%, 70%, and 50%) for five minutes 
each. AgNOR staining was carried out using a solution consisting of one volume of 2% 
gelatine in 1% aqueous formic acid and two volumes of 50% silver nitrate (Merck, 
Darmstadt, Nr: 1.04080.0100, Nr: 1.00263.1000, Nr: 1.01510.0050). The incubation 
was performed at RT for 35 minutes in the dark. After staining the slides were placed in 
a dark container, washed three times in double distilled water and passed for ten 
minutes in 10% Na-thiosulfate (Merck, Darmstadt, Nr: 1.09147.1000). The smears were 
then washed for five minutes in tap water and dehydrated in increasing ethanol 
concentrations (50%, 70%, 96% and 100%) for five minutes each. The slides were then 
immersed in xylene for five minutes, covered with Entellan (Merck, Darmstadt, Nr: 
1.07961.0500) and stored in the dark. 
 
2.6.2 Counting procedure 
AgNOR counting was performed on 100 cells for each cytologic smear. These were 
examined at 1,000x magnification under oil immersion. Unequivocally benign cells 
were excluded from counting in malignant effusions, and only reactive mesothelial cells 
were counted in benign effusion samples. To standardize counting, we followed 
Crocker’s method Crocker et al. 1989 with minor modifications as follow: first, silver-stained 
dot aggregations or partly disaggregated nucleoli (clusters) treated as one structure were 
counted. Second, individual dots (satellites) outside the clusters of silver-stained 
structures were counted. Third, clusters and satellites were counted together to obtain 
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the total AgNORs counts. The mean number per nucleus of AgNORs as clusters, as 
satellites, and as total AgNOR counts (clusters plus satellites) were calculated in each 
case. The counting procedure took 30-60 minutes per smear. For a correct rate of tumor 
cell identification and to avoid the overlap between reactive and malignant cells in 
effusions, we applied our experimentally found threshold of 2.5 AgNOR dots as 
satellites and 4.5 as total AgNOR counts 
Pomjanski et al. 2001
.  
 
2.7 Fluorescence in situ hybridization (FISH) 
2.7.1 FISH procedure 
For FISH analysis, additional Cytospin slides were made from each specimen. Native 
materials were centrifuged at 400g for five minutes (Rotina 46 centrifuge, Hettich 
GmbH, Tuttlingen, Germany). The supernatant was discarded. The pellet was 
resuspended in 10 ml Saccomano fixative (50% ethanol, 2% polyethylene glycol 1.500 
and 60mg/L rifampicin), fixed for 30 minutes and recentrifuged. The sediment (40-
70µl) was resuspended in 1 ml supernatant and centrifuged at 125g for ten minutes 
using a Cytospin centrifuge (Shandon Cytospin 3, Thermo Electron Corporation, 
Dreieich, Germany). The slides were stained according to Papanicolaou to verify the 
presence of mesothelial, atypical mesothelial, mesothelioma or carcinoma cells. 
 
In each Papanicolaou stained Cytospin slide, the LSI p16/CEP 9 dual color probe was 
performed (descriptioned below). The laboratory procedure was performed according to 
the recommendations of the manufacturer (Abbot/Vysis, Downers Grove, IL), with 
minor modifications. Briefly, slides were uncovered in xylene, rehydrated through two 
series of 100%, 95% and 80% ethanol, placed under running tap water for five minutes, 
then in 0.5% HCl in 70% ethanol for 15 minutes at RT and placed under running tap 
water again for five minutes. After immersion in 2X saline sodium citrate (SSC) for five 
minutes at 73ºC, slides were digested by using 0,2mg/ml pepsin in 0,01 mol/L HCl for 
15 minutes at 37ºC in a humidified chamber. The slides were washed in phosphate 
buffered saline (PBS) for five minutes at RT, fixed in 1% neutral buffered formalin/PBS 
for five minutes, washed in PBS again for five minutes, dehydrated in increasing 
ethanol concentrations (70%, 85%, and 100%) for two minutes each and air–dried at 
RT. The FISH probe mix (7µl LSI/WCP hybridization buffer, 2µl purified water and 
1µl 9p21 probe) was applied on the selected target area of slide, cover-slipped and 
sealed with rubber cement (Q- Biogene, Nr: FIXO 0125). After denaturation at 73ºC for 
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ten minutes, slides were incubated at 37ºC overnight in a humidified chamber. After 
hybridization the samples were washed in 0.4X SSC/ 0.1% NP-40 at 73ºC and in 0.4X 
SSC/ 0.1% NP-40 at RT for 2 minutes each. Then DAPI II counterstain (4.6-diamidine-
2-2phenylindole dihydrochloride) (Abbot/Vysis, Downers Grove, IL, Nr: 6J5001/32-
804831) was used for counterstaining and the slides were stored in the dark at -20ºC 
until signal counting was performed. 
 
2.7.1.1 DNA Probe Description 
The LSI p16/CEP 9 dual color probe (Abbot/Vysis, Downers Grove, IL, Nr: 6J6701/32-
804826) is designed to detect 9p21 deletions and is a mixture of the LSI p16 probe 
labeled with SpectrumOrange and the CEP 9 probe labeled with SpectrumGreen (Figure 
4). The LSI p16 SpectrumOrange probe spans approximately 190 kb and contains a 
number o genetic loci including D9S1749, D9S1747, p16 (INK4A), p14 (ARF), 
D9S1748, p15 (INK4B) and D9S1752 (Figure 5). The CEP 9 SpectrumGreen probe 
hybridizes to alpha satellite sequences specific to chromosome 9. 
 
   
Figure 4: Ideogram of                 Figure 5: Schematic probe map of chromosome region 9p21 
       LSI p16 and CEP 9 
 
2.7.1.2 Results of Hybridization 
In a normal sample, the expected result for a nucleus hybridized with the LSI p16/CEP 
9 probe is the two orange, two green (2O2G) signal pattern. If a deletion at the 190 kb 
region covered by the LSI p16 probe occurs on one chromosome 9 homolog and both 
centromeres from chromosome 9 are retained, the one orange, two green (1O2G) signal 
pattern is expected. Very small deletions may occur that do not delete the entire LSI p16 
probe target and therefore will not be detected. 
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2.7.2 Scoring 
The slides were scored on a cell-by-cell basis using a Zeiss Axio Imager M1 
fluorescence microscope (Zeiss, Göttingen, Germany) (Figure 6) with a single-band 
pass filter for DAPI (DAPI counterstain), SpectrumGreen (chromosome 9) and 
SpectrumOrange (9p21 locus). It contains a 63x and a 100x planar objectives and a 
charge-coupled device black-and-white video camera with 1.4 Megapixel (AxioCam 
MRm, München-Hallbergmoos, Germany) and it is equipped with the Axio Vision 
QuantiFISH software (Zeiss, Hallbergmoos, Germany).  
 
 
Figure 6: Zeiss Axio Imager M1 Fluorescence Microscope Workstation. 
 
Signal counting was performed by an independent observer, experienced with FISH 
analysis. A minimum of 100 cells per case was counted manually under 100x objective 
in a continuous manner whenever possible. The abnormal cells, if present, were selected 
based on nuclear enlargement, irregular nuclear shape and patchy (i.e., 
nonhomogeneous) DAPI staining. Inflammatory cells and macrophages were not 
counted. Two staining colors, orange for 9p21 locus and green for CEP 9, were 
simultaneously counted in a given nucleus whenever possible. In each specimen, 
nonmesothelial cells (polymorphonuclear cells and lymphocytes) served as internal 
controls and hybridization was evaluated in these cells to check for hybridization 
efficiency. Specifically, only bright, compact signals having similar fluorescence 
intensity were counted, whereas overlapping nuclei, such as those in papillary clusters, 
were not counted. Diffuse and split signals were counted as one signal each.  
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Homozygous deletion was defined as absence of both 9p21 signals in the presence of at 
least one chromosome 9 centromere signal. Heterozygous deletion was defined as 
presence of only one 9p21 signal or when the number of 9p21 signals was lower than 
the number of chromosome 9 centromere signals. 
 
2.8 Follow up 
According to patient follow up the investigated effusions were classified as either 
containing malignant cells or not, and what kind of tumor is present when the patient 
presented malignancy. Patient history was only accepted for evaluation if it 
retrospectively presented sufficient evidence for the presence or absence of tumor cells 
in effusions. These revealed either histological and/or clinical follow up. Clinical 
evidence was considered valid, applying such diagnostic techniques as radiology and/or 
computer tomography. 
 
If there were no discrepancies between the cytological diagnosis and the medical report, 
the diagnosis was considered as truly negative or positive. It was classified as false 
negative or false positive when there were discrepancies between the cytological 
diagnosis and the patient’s follow up. 
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3 Objectives 
The aim of this study was to find out the prevalence of hetero- and homozygous 
deletions at chromosome region 9p21 (targeting the CDKN2A gene) in abnormal 
mesothelial cells in effusions of the body cavities using FISH to differentiate malignant 
mesothelioma from reactive mesothelial cells and these from those of metastatic 
carcinomas.  
 
We furthermore wanted to compare the diagnostic usefulness of cytomorphology, 
DNA-ICM, immunocytochemistry, AgNOR-analysis and chromosomal FISH alone or 
in combination for the cytological diagnosis of early malignant mesothelioma in serous 
effusions, in comparison with metastatic carcinoma and reactive mesothelial cells.
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4 Results 
4.1 Conventional cytology 
The usefulness of 9p21 deletions as a diagnostic marker, cytomorphology and other 
adjuvant methods (DNA-ICM, immunocytochemistry and AgNOR-analysis) for the 
differential diagnosis of malignant mesothelioma (MM), metastatic carcinoma and 
reactive mesothelial cells in effusions, was investigated by correlation of cytologic 
diagnoses with histologic and/or clinical follow-up. 
 
From 33 cases cytologically diagnosed as suspicious or positive for MM, two cases 
were re-evaluated after the application of adjuvant methods (immunocytochemistry, 
DNA-ICM, and AgNOR-analysis) (Figure 7). One case primarily reported as suspicious 
for MM was revised as negative for tumor cells after the routine application of adjuvant 
methods, but histologic and clinical follow-up confirmed a MM. The other case was re-
diagnosed as metastatic non-small cell carcinoma after the results of adjuvant methods 
were available, but it was finally confirmed as MM by histologic follow-up. Another 
case diagnosed as suspicious for MM continued to be suspicious even after the 
application of adjuvant methods, which was confirmed as MM after histologic follow 
up.  
 
 
Figure 7: Flow chart illustrating the diagnostic results. MM indicates malignant mesothelioma; CA, 
carcinoma. 
 
One case cytologically reported as negative for tumor cells was not corroborated by 
histologic follow-up, which revealed a pleural involvement of a Non-Hodgkin 
Lymphoma. In consequence, the effusions used for application of adjuvant methods 
after follow-up diagnoses are resumed as 31 cases with metastatic carcinomas and 39 
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with reactive mesothelial cells. In four cases containing reactive mesothelial cells, we 
did not obtain their follow-up. All other tumor cell-negative cases were confirmed by 
follow-up. The most often found etiologies of effusions in those patients were: 
pulmonary emphysema, pneumonia, congestive heart failure, coronary disease, renal 
insufficiency, cirrhosis of the liver, rheumatic fever, chronic inflammation and foreign 
substances like talc. 
 
All cases of metastatic carcinomas in the current study were confirmed by follow-up. 
The primary tumors metastasized to the pleura were localized in the breasts (12), the 
lungs (3), the ovaries (3), the stomach (1) and the endometrium (1). In peritoneal 
carcinosis, the primary tumors came from metastatic carcinomas of the ovary (6), the 
stomach (2), the pancreas (1), the endometrium (1), and the breast (1). 
 
4.2 DNA-image cytometry (DNA-ICM) 
None (0/39) of the DNA-histograms obtained from tumor cell-negative effusions 
containing reactive mesothelial cells revealed any of the mentioned parameters of DNA-
aneuploidy (described in Material and Methods) and were therefore all interpreted as 
DNA-euploid (Figure 8 and 9). This corresponds to a prevalence of 100% of the DNA-
euploidy in reactive mesothelial cells (Table 4).  
 
The DNA histograms of effusions containing malignant cells presented one or two 
parameters of DNA aneuploidy. All effusions due to metastatic carcinomas and 22/31 
due to mesotheliomas were DNA aneuploid (Table 4). This represents a prevalence of 
DNA aneuploidy in malignant cells in effusions of 100% for metastatic carcinomas and 
71% for mesotheliomas. In two cases of MM, DNA-ICM was not performed due to 
scarcity of cells. 
 
Table 4: Prevalence of DNA-aneuploidy in tumor cell-positive and -negative effusions 
 
DNA ploidy 
status 
Follow-up diagnosis 
Without tumor cells 
n=39 (%) 
Total with tumor cells 
n=62 (%) 
 Carcinoma 
n=31 (%) 
Mesothelioma 
n=31 (%) 
Euploidy  39 (100.0) 9 (14.5)  0 (0.0) 9 (29.0) 
Aneuploidy  0 (0.0) 53 (85.5)  31 (100.0) 22 (71.0) 
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The prevalence of DNA-aneuploidy in effusions using different algorithms is 
summarized in Table 5. Single-cell aneuploidy was detected in 86.4% (19/22) of MM 
and an abnormal DNA-stemline in 54.5% (12/22) of cases. In metastatic carcinomas, 
80.6% (25/31) showed one, two, or more aneuploid DNA stemlines, and single-cell 
aneuploidy was detected in 83.9% (26/31). While 64.5% (20/31) of metastatic 
carcinomas showed stemline- and single-cell aneuploidy, only 40.9% (9/22) of MM 
showed both aspects of DNA aneuploidy. Single-cell aneuploidy was the most frequent 
type of aneuploidy detected in 84.9% (45/53) of all patients with tumor cells (Table 5).  
 
Table 5: Prevalence of DNA-aneuploidy in effusions according to the application of different algorithms 
 DNA-aneuploidy 
 
 
Cytology 
 
N
o
. of 
cases 
  
Single-cell 
aneuploidy (%) 
 
STL 
aneuploidy (%) 
Single-cell 
and STL 
aneuploidy (%) 
Malignant mesothelioma 22  19 (86.4) 12 (54.5) 9 (40.9) 
Metastatic carcinomas 31  26 (83.9) 25 (80.6) 20 (64.5) 
Total with tumor cell 53  45 (84.9) 37 (69.8) 29 (54.7) 
DNA-ICM: DNA-image cytometry; STL: stemline; Single-cell aneuploidy: at least one cell with DNA 
content >9c 
 
 
Figure 8 to 14 illustrate the histograms revealing the parameters used for DNA-ICM 
diagnostic interpretation in the current study. 
 
While 61.3% (19/31) of MM showed their greatest DNA stemline within the range of 
1.8c and 2.2c and/or 3.6c and 4.4c (Figure 13), only 19.4% (6/31) of metastatic 
carcinomas showed their greatest stemline in this region. 
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 Figure 8: DNA histogram showing an euploid-
diploid pattern (a single DNA-stemline near 2c 
and only a few values at 4c; 9cEE = 0). 
Figure 9: DNA histogram showing an euploid-
polyploid pattern (DNA-stemlines at 2c and 
4c, with DNA-stemlines at 2c containing most 
of the cells; 9cEE = 0). 
Figure 10: DNA histogram indicating DNA-
stemline aneuploid (stemlines 3,36c and 6,72c; 
9cEE = 0). 
Figure 11: DNA histogram showing an 
aneuploid-multiploid pattern (an abnormal 
DNA-stemline which is different at a statistical 
significant level from those of normal cell 
population; 9cEE = 2). 
4 Results  29 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: DNA histogram showing aneuploid-
tetraploid pattern (a second DNA-stemline at 4c 
comprising more cells than the first one; 9cEE 
= 0). 
Figure 13: DNA histogram showing single-cell 
aneuploidy (a normal DNA-stemline at 2c, 4c 
and 8c, with at least one cell with DNA content 
> 9c). 
Figure 14: DNA histograms showing stemlines 
and single-cell aneuploidy (stemlines at 3,19c 
and 6,4c; 9cEE = 2). 
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4.3 Immunocytochemistry 
The immunocytochemical results are summarized in table 6 to 8 and illustrated in 
figures 15 to 17. All 32 cases of MM demonstrated positivity with calretinin. In the 
majority of cases, the staining reaction was strong and diffuse (>80% of tumor cells) 
(Figure 15a). From two effusions from the same patient, immunocytochemistry was 
performed in only one case. BerEp4 were negative in 27 (84.4%) cases of MM (Figure 
15b). In five cases it showed positivity. Only two cases demonstrated strong reaction (> 
80%) with BerEP4, in which calretinin demonstrated also strong reaction in tumor cells. 
EMA and mesothelin showed positivity in the majority of cases of MM and WT-1 in 
66.7% (Table 6). 
 
Table 6: Immunocytochemical findings in malignant mesotheliomas 
 
Markers 
N
o
. of 
cases 
Negative 
(%) 
Positive 
(%) 
 Grading of positive reactivity 
11-39% 40-79% 80-100% 
BerEP4 32 27 (84.4) 5 (15.6)  3 0 2 
Calretinin 32 0 (0.0) 32 (100.0)  1 1 30 
EMA 28 2 (7.1) 26 (92.9)  3 3 20 
Mesothelin 11 1 (9.1) 10 (90.9)  2 2 6 
WT-1 15 5 (33.3) 10 (66.7)  3 1 6 
BerEP4: surface and cytoplasmic glycoprotein; EMA: epithelial membrane antigen; WT-1: Wilms’ tumor 
protein 1 
 
Calretinin was negative in all cases of effusions containing metastatic carcinomas 
(Figure 16a) (Table 7). In 87.1% of those cases, BerEP4 showed positivity (Figure 16b). 
In two cases of metastatic carcinoma of the breast, one of the ovary, and one of the 
stomach, calretinin and BerEP4 were negative.  
 
Table 7: Immunocytochemical findings in metastatic carcinomas 
 
Markers 
N
o
. of 
cases 
Negative 
(%) 
Positive 
(%) 
 Grading of positive reactivity 
11-39% 40-79% 80-100% 
BerEP4 31 4 (12.9) 27 (87.1)  2 3 22 
Calretinin 31 31 (100.0) 0 (0.0)  0 0 0 
BerEP4: surface and cytoplasmic glycoprotein 
 
The majority of negative cases with reactive mesothelial cells demonstrated positivity 
with calretinin (Figure 17a) (Table 8). BerEP4 was completely negative in all of them 
(Figure 17b). Two cases that showed no reaction with calretinin were also negative with 
BerEP4. 
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Table 8: Immunocytochemical findings in reactive effusions 
 
Markers 
N
o
. of 
cases 
Negative 
(%) 
Positive 
(%) 
 Grading of positive reactivity 
11-39% 40-79% 80-100% 
BerEP4 39 39 (100.0) 0 (0.0)  0 0 0 
Calretinin 39 2 (5.1) 37 (94.9)  17 13 7 
BerEP4: surface and cytoplasmic glycoprotein 
 
    
Figure 15: a) Malignant mesothelioma cells stained with calretinin (x400). b) Malignant mesothelioma 
cells faintly stained with BerEP4 (x400). 
 
    
Figure 16: a) Metastatic carcinoma cells of the ovary stained with calretinin (x200). b) Metastatic 
carcinoma cells of the ovary stained with BerEP4 (x200). 
 
    
Figure 17: a) Reactive mesothelial cells stained with calretinin (x400). b) Reactive mesothelial cells 
stained with BerEP4 (x400). 
a b 
a b 
a b 
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4.4 Silver staining of nucleolar organizer regions-associated proteins 
(AgNORs) 
AgNORs were strictly located only within nuclei and were clearly visible as distinct 
black or brown dots. AgNORs were counted as clusters if silver-stained dot 
aggregations were found within nucleoli. AgNORs were counted as satellites if 
individual dots were detected outside clusters. Total AgNOR counts were obtained 
counting clusters and satellites together. 
 
We could not perform AgNOR counting in ten cases (four negatives, one metastatic 
carcinoma and five MMs) due to small number of cells, overlap of cells or technical 
staining problems as hyper- or hypostaining with silver nitrate.  
 
As described in our previous study 
Pomjanski et al. 2001
,
 
the total AgNOR count and that of 
satellites were the most efficient method of diagnostic analysis. We confirmed this 
statement in the current study comparing the results from MM, metastatic carcinoma 
and reactive effusions (Figures 18 and 19). Using AgNOR cluster-counting, no 
difference between reactive mesothelial- and tumor cells was found (Figure 20). To 
validate those thresholds, we generated receiver-operator characteristic (ROC) curves 
with our results for MM (Figures 21 to 23), for metastatic carcinomas (Figures 24 to 
26), and for all tumors together (MM plus metastatic carcinoma) (Figures 27 to 29). The 
ROC curves visualize the effect of various cutoffs on diagnostic sensitivity and 
specificity of the AgNOR-analysis. We applied the threshold of 2.5 AgNOR dots as 
satellites and 4.5 as total AgNOR counts.  
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Figure 18: Distribution of mean AgNOR number per nucleus (Total AgNOR counts) in reactive 
mesothelial cells (negative), malignant mesotheliomas and metastatic carcinomas. 
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Figure 19: Distribution of mean AgNOR number as satellites per nucleus in reactive mesothelial cells 
(negative), malignant mesotheliomas and metastatic carcinomas. 
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Figure 20: Distribution of mean AgNOR number as clusters per nucleus in reactive mesothelial cells 
(negative), malignant mesotheliomas and metastatic carcinomas. 
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Figure 21: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for malignant mesotheliomas detection based on the number of total AgNOR counts. 
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Figure 22: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for malignant mesotheliomas detection based on the number of AgNOR satellites. 
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Figure 23: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for malignant mesotheliomas detection based on the number of AgNOR clusters. 
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Figure 24: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for metastatic carcinomas detection based on the number of total AgNOR counts. 
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Figure 25: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for metastatic carcinomas detection based on the number of AgNOR satellites. 
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Figure 26: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for metastatic carcinomas detection based on the number of AgNOR clusters. 
4 Results  36 
Total AgNOR counts
6.0
5.5
5.0
4.5
4.0 3.5 3.0 2.5 2.0
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
1 - Specificity (false-positive)
S
en
si
ti
v
it
y
 
Figure 27: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for tumor cells (malignant mesotheliomas + metastatic carcinomas) detection based on 
the number of total AgNOR counts. 
 
AgNOR Satellites
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0 1.5 1.0 0.5
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
1 - Specificity (false-positive)
S
en
si
ti
v
it
y
 
Figure 28: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for tumor cells (malignant mesotheliomas + metastatic carcinomas) detection based on 
the number of AgNOR satellites. 
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Figure 29: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
AgNOR-analysis for tumor cells (malignant mesotheliomas + metastatic carcinomas) detection based on 
the number of AgNOR clusters.  
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The AgNOR dots were discrete and smaller in benign effusion cases (Figure 30) as 
compared to coarse and aggregated in malignant effusion (Figures 31 and 32).  
 
    
Figure 30: Benign reactive mesothelial cells with small and discrete AgNOR dots (clusters) and a low 
number of satellites (oil immersion, left: x630, right: x1000). 
 
    
Figure 31: Case of malignant mesothelioma manifesting a moderately increased AgNOR number. The 
clusters are characterized by their irregular form. In many cells high counts of satellites are visible (oil 
immersion, left: x630, right: x1000). 
 
    
Figure 32: Case of a metastatic carcinoma of the ovary in effusion containing nuclei with numerous small 
and large AgNOR dots as clusters and satellites irregularly distributed (oil immersion, left: x630, right: 
x1000). 
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In malignant mesothelioma cases, 89.3% showed ≥ 2.5 AgNOR dots as satellites and ≥ 
4.5 as total AgNOR counts (Table 9). In one case the AgNOR-analysis showed 
2.16/3.16 (satellites/total AgNOR counts); this case was initially reported as suspicious 
for MM and, after the application of adjuvant methods, it was re-evaluated as negative, 
but histologic and clinical follow-up confirmed a MM. Two doubtful cases were found 
with 2.30/4.92 and 3.04/4.48 (satellites/total AgNOR counts), demonstrating that 
counting of satellites or the total AgNOR counts were not enough to target the threshold 
established. The mean number of satellites was 4.91 (range, 2.16-11.4) and the total 
AgNOR counts was 7.04 (range, 3.16-13.9) in the MM cases. 
 
Table 9: Prevalence of AgNOR-analysis in tumor cell-positive and negative effusions 
AgNOR-analysis  
(satellites/total 
AgNOR counts) 
Follow-up diagnosis 
Without tumor cells 
n=35 (%) 
Total with tumor cells 
n=58 (%) 
 Carcinoma 
n=30 (%) 
Mesothelioma 
n=28 (%) 
< 2.5 / < 4.5  34 (97.1) 1 (1.7)  0 (0.0) 1 (3.6) 
≥ 2.5 / ≥ 4.5  1 (2.9) 54 (93.1)  29 (96.7) 25 (89.3) 
Doubtful* 0 (0.0) 3 (5.2)  1 (3.3) 2 (7.1) 
AgNOR: silver staining of nucleolar organizer regions-associated proteins; * Doubtful represents the 
cases that satellites or the total AgNOR counts is contradictory (<2.5 / >4.5 or >2.5 / <4.5).  
 
 
In 29/30 (96.7%) of metastatic carcinoma cases showed ≥ 2.5 AgNOR dots as satellites 
and ≥ 4.5 as total AgNOR counts (Table 9). In only one case of metastatic carcinoma of 
the breast the AgNOR-analysis was doubtful with 2.44/5.16 (satellites/total AgNOR 
counts). In metastatic carcinoma cases, the mean number of satellites was 5.31 (range, 
2.44-10.44) and the total AgNOR counts was 7.04 (range, 4.64-12.3). 
 
Only one case of negative effusion demonstrated an increased number of AgNOR dots 
(2.5 as satellites and 5.13 as total AgNOR counts). This patient was clinically diagnosed 
as holding lung embolism and pneumonia without indication of malignant cells in 
effusion. 97.1% of negative cases showed < 2.5 AgNOR dots as satellites and < 4.5 as 
total AgNOR counts (Table 9). The mean number of satellites was 1.07 (range, 0.43-
2.5) and the total AgNOR counts was 2.94 (range, 2.1-5.13) in reactive mesothelial 
cells. 
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4.5 Fluorescence in situ hybridization (FISH) 
To characterize our FISH assay, we determined hybridization patterns in 33 malignant 
mesotheliomas, 31 metastatic carcinomas and 39 reactive mesothelial cells confirmed 
by histologic and/or clinical follow-up. Homozygous deletion indicates total absence of 
9p21 signals, and heterozygous deletion indicates partial deletion (with only 1 9p21 
signal or when the number of 9p21 signals was lower than the number of chromosome 9 
centromere signals). A summary of distribution of 9p21 homo- and heterozygous 
deletion number per nucleus in the current study is presented in Figure 33 and 34, 
respectively. 
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Figure 33: Distribution of 9p21 homozygous deletion number per nucleus in reactive mesothelial cells 
(negative), malignant mesotheliomas and metastatic carcinomas. 
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Figure 34: Distribution of 9p21 heterozygous deletion number per nucleus in reactive mesothelial cells 
(negative), malignant mesotheliomas and metastatic carcinomas. 
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Receiver-operator characteristic (ROC) curves with our results for MM (Figures 35 and 
36), for metastatic carcinoma (Figures 37 and 38), and for tumor cells (MM plus 
metastatic carcinoma) (Figures 39 and 40) were generated to determine the effect of 
various cutoffs on the sensitivity and specificity of the FISH assay. To avoid over 
interpretation of incomplete hybridization, we considered as positive all specimens 
containing ≥ 5 nuclei showing homo- or ≥ 15 nuclei showing heterozygous deletion of 
9p21. We focused on both homozygous and heterozygous deletion of 9p21 as the 
criterion for positivity due to the relatively low frequency of these events in normal cell 
population. 
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Figure 35: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
FISH assay for malignant mesothelioma detection based on the number of cells with 9p21 homozygous 
deletion. 
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Figure 36: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
FISH assay for malignant mesothelioma detection based on the number of cells with 9p21 heterozygous 
deletion. 
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Figure 37: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
FISH assay for metastatic carcinoma detection based on the number of cells with 9p21 homozygous 
deletion. 
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Figure 38: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
FISH assay for metastatic carcinoma detection based on the number of cells with 9p21 heterozygous 
deletion. 
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Figure 39: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
FISH assay for tumor cells (malignant mesothelioma + metastatic carcinoma) detection based on the 
number of cells with 9p21 homozygous deletion. 
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Figure 40: Receiver-operator characteristic (ROC) curve showing the sensitivity and specificity of the 
FISH assay for tumor cells (malignant mesothelioma + metastatic carcinoma) detection based on the 
number of cells with 9p21 heterozygous deletion. 
 
 
Prevalence of 9p21 deletion in cases of reactive mesothelial cells, malignant 
mesothelioma and metastatic carcinoma, using as cutoffs ≥ 5 nuclei of homo- or ≥ 15 
nuclei of heterozygous deletion of 9p21 is summarized in Table 10 and illustrated in 
Figures 41 and 42. FISH were positive for 9p21 deletion in 30/33 (90.9%) of malignant 
mesotheliomas cases; 16 (48.5%) showed 9p21 homozygous deletion (Figure 42a), 12 
(36.4%) 9p21 heterozygous deletion (Figure 42b), and 2 (6.0%) both. 
 
Table 10: Prevalence of 9p21 deletion in cases of reactive mesothelial cells, malignant mesothelioma and 
metastatic carcinoma  
  9p21 deletion (%)  Type of FISH positivity (%) 
 
 
Cytology 
 
N
o
 of 
cases 
  
FISH 
negative 
 
FISH 
positive 
  
Homo 
deletion 
 
Hetero 
deletion 
Homo and 
Hetero 
deletion 
Reactive mesothelial cell 39  39 (100) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 
Malignant mesothelioma 33  3 (9.1) 30 (90.9)  16 (48.5) 12 (36.4) 2 (6.0) 
Metastatic carcinomas 31  17 (54.8) 14 (45.2)  4 (12.9) 8 (25.8) 2 (6.5) 
FISH: fluorescence in situ hybridization. Positive homozygous (homo) deletion of 9p21 ≥ 5 nuclei; 
positive heterozygous (hetero) deletion ≥ 15 nuclei 
 
 
From 31 metastatic carcinomas cases, FISH was positive for 9p21 deletion in 14 
(45.2%); only 4 (12.9%) showed 9p21 homozygous deletion, 8 (25.8%) 9p21 
heterozygous deletion, and 2 (6.5%) both (Table 10). The cases with 9p21 homozygous 
deletion were carcinoma of the breast, the ovary, the pancreas, and the endometrium. 
Two cases of carcinoma of the ovary showed 9p21 homo- and heterozygous deletion. 
The 9p21 heterozygous deletion cases were carcinoma of the endometrial (1), the lung 
(1), the stomach (2), the breast (2), and the ovary (2).  
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The 9p21 deletion was not detected in any of 39 cytologically of negative effusions, 
containing reactive mesothelial cells (Figure 41) (Table 10). One case cytologically 
diagnosed as tumor cell-negative effusion demonstrated positivity of 9p21 homozygous 
deletion, and the histologic follow-up reported a Non-Hodgkin lymphoma. Another case 
was initially diagnosed cytologically as suspicious for MM and re-diagnosed as 
negative after adjuvant methods (DNA-ICM, immunocytochemistry and AgNOR-
analysis), but histologic and clinical follow-up confirmed a MM. In this case, FISH 
demonstrated 9p21 heterozygous deletion.  
 
 
    
Figure 41: Fluorescence in situ hybridization showing: left: two signals for chromosome 9 centromeric 
probe (CEP-9; Spectrum Green) and two signals for the 9p21 locus probe (LSI p16; Spectrum Orange) in 
reactive mesothelial cells; right: four signals for chromosome 9 centromeric probe and four signals for the 
9p21 locus in reactive mesothelial cell. 
 
 
   
Figure 42: Fluorescence in situ hybridization showing: a) left: two signals for chromosome 9 centromeric 
probe (CEP-9; Spectrum Green) and no signals for the 9p21 locus probe (LSI p16; Spectrum Orange) in 
malignant mesothelioma nuclei; b) right: two signals for chromosome 9 centromeric probe and only one 
signal for the 9p21 locus in malignant mesothelioma nuclei. 
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4.6 Comparison of adjuvant methods 
In the current study, when cytology was used alone for the diagnosis of MM, 81.8% of 
cases were reported with certainty as tumor cell-positive. The addition of DNA-ICM 
improved the prevalence of positivity to 87.9% and the addition of AgNOR to 97% 
(Table 11). The application of FISH to reveal 9p21 deletions improved the prevalence 
of correct MM diagnosis to 100%, especially when 9p21 homo- and heterozygous 
deletion were used as parameters. 
 
Table 11: Prevalence of cytology correlated with one adjuvant method in effusions with malignant 
mesothelioma cells 
 No. of 
Cases 
 
Cytology 
Cytology + 
DNA-ICM 
1 
Cytology + 
AgNOR 
2
 
Cytology + FISH 
3 
Homo Homo & Hetero 
Prevalence 
    (%) 
33 27 
(81.8) 
29 
(87.9) 
32 
(97.0) 
30 
(90.9) 
33 
(100.0) 
1 DNA-ICM: DNA-image cytometry. DNA-aneuploidy; 2 AgNOR: silver staining of nucleolar organizer 
regions-associated proteins. ≥2.5 / ≥4.5 (satellites / total AgNOR counts); 3 FISH: Fluorescence in situ 
hybridization. Positive homozygous (homo) deletion of 9p21 ≥ 5 nuclei; positive heterozygous (hetero) 
deletion ≥ 15 nuclei 
 
 
Thus, combining cytology, DNA-ICM, AgNOR-analysis and FISH (Table 12) lead to 
an increase in detection of malignant mesothelioma cells in serous effusions.  
 
Table 12: Prevalence of cytology correlated with more than one adjuvant method in malignant 
mesothelioma cases 
  
 
 
N
o
. of 
cases 
 
 
Cytology + 
DNA-ICM
1
 
+ AgNOR
2 
Cytology + 
DNA-ICM 
1
 + 
FISH
3
 
Cytology + 
AgNOR 
2
 + 
FISH
3
 
Cytology + DNA-
ICM 
1
 + AgNOR 
2
 
+ FISH 
3
 
Homo Homo & 
Hetero 
Homo Homo & 
Hetero 
Homo Homo & 
Hetero 
Prevalence 
    (%) 
33 32 
(97.0) 
31 
(93.9) 
33 
(100.0) 
32 
(97.0) 
33 
(100.0) 
32 
(97.0) 
33 
(100.0) 
1 DNA-ICM: DNA-image cytometry. DNA-aneuploidy; 2 AgNOR: silver staining of nucleolar organizer 
regions-associated proteins. ≥2.5 / ≥4.5 (satellites / total AgNOR counts); 3 FISH: Fluorescence in situ 
hybridization. Positive homozygous (homo) deletion of 9p21 ≥ 5 nuclei; positive heterozygous (hetero) 
deletion ≥ 15 nuclei 
 
 
The utility of adjuvant methods using specific algorithm showed different prevalences 
in the MM cases (Table 13). DNA aneuploidy was found in 71% of these cases. The 
parameter of AgNOR-analysis used in the current study (≥ 2.5 satellites / ≥ 4.5 total 
AgNOR counts) was present in 89.3% of MM cases. The prevalence of 9p21 
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homozygous deletion in patients with MM was 54.5%, but increase to 90.9% when both 
9p21 homo- and heterozygous deletion was used as parameter. 
 
Table 13: Prevalence of individually adjuvant methods in effusions due to malignant mesothelioma 
according to the application of different algorithms 
 DNA-ICM 1 AgNOR 2 FISH 3 
Homo Homo & Hetero 
Prevalence (%) 22/31 (71.0) 25/28 (89.3) 18/33 (54.5) 30/33 (90.9) 
1 DNA-ICM: DNA-image cytometry. DNA-aneuploidy; 2 AgNOR: silver staining of nucleolar organizer 
regions-associated proteins. ≥2.5 / ≥4.5 (satellites / total AgNOR counts); 3 FISH: Fluorescence in situ 
hybridization. Positive homozygous (homo) deletion of 9p21 ≥ 5 nuclei; positive heterozygous (hetero) 
deletion ≥ 15 nuclei 
 
 
Using those parameters of respective adjuvant methods, the prevalence increased when 
they were combined (Table 14). DNA-ICM and AgNOR-analysis were found in 96.8% 
of MM cases. If AgNOR was combined to FISH, the prevalence increases to 97% using 
9p21 homo- and heterozygous deletion. The use of DNA-ICM, AgNOR and FISH 
together recognized all cases of MM. 
 
Table 14: Prevalence of combined adjuvant methods in effusions due to malignant mesothelioma 
according to the application of different algorithms 
  
 
DNA-ICM 
1
 
+ AgNOR 
2
 
DNA-ICM 
1
 + 
FISH 
3 
AgNOR 
2
 + 
FISH 
3 
DNA-ICM 
1
 + 
AgNOR 
2
 + FISH 
3 
Homo Homo & 
Hetero 
Homo Homo & 
Hetero 
Homo Homo & 
Hetero 
Prevalence  
    (%) 
30/31 
(96.8) 
30/33 
(90.9) 
33/33 
(100.0) 
29/33 
(87.9) 
32/33 
(97.0) 
32/33 
(97.0) 
33/33 
(100.0) 
1 DNA-ICM: DNA-image cytometry. DNA-aneuploidy; 2 AgNOR: silver staining of nucleolar organizer 
regions-associated proteins. ≥2.5 / ≥4.5 (satellites / total AgNOR counts); 3 FISH: Fluorescence in situ 
hybridization. Positive homozygous (homo) deletion of 9p21 ≥ 5 nuclei; positive heterozygous (hetero) 
deletion ≥ 15 nuclei 
 
 
To differentiate metastatic carcinoma from MM or reactive mesothelial cells, the 
application of calretinin and BerEP4 plays an important role. Calretinin should be 
positive in MM cells but negative in epithelial cells, while BerEP4 should be positive in 
epithelial cells and negative in MM cells. As expected, calretinin was found in all cases 
of MM and was negative in all cases of metastatic carcinoma (Table 15). Yet, BerEP4 
were found in 15.6% of MM, 87.1% of metastatic carcinoma and 0% of negative 
effusions. The combination of calretinin positive and BerEP4 negative were found in 
84.4% of MM cases. The addition of DNA-polyploidy as a diagnostic increased the 
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prevalence to 90.6% and to 100% if 9p21 homozygous deletion were applied to MM 
cases.  
 
Table 15: Prevalence of immunocytochemistry, DNA-polyploidy and 9p21 homozygous deletion to 
differentiate malignant mesothelioma from metastatic carcinoma in serous effusions  
 Malignant 
Mesothelioma 
Metastatic 
Carcinoma 
DNA-polyploidy 19/31 (61.3%) 6/31 (19.4%) 
Calretinin 32/32 (100.0%) 0/31 (0.0%) 
BerEP4 5/32 (15.6%) 27/31 (87.1%) 
9p21 homozygous deletion 18/33 (54.5%) 6/31 (19.4%) 
Calretinin / BerEP4 27/32 (84.4%) 1 27/31 (87.1%) 2 
Calretinin / BerEP4 + DNA-polyploidy 29/32 (90.6%) 1 28/31 (90.3%) 2 
Calretinin / BerEP4 + 9p21 homozygous deletion 32/32 (100%) 1 27/31 (87.1%) 2 
Calretinin / BerEP4 + DNA-polyploidy + 9p21 
homozygous deletion 
32/32 (100%) 
1
 28/31 (90.3%) 
2
 
DNA-polyploidy: greatest DNA stemline within the range 1.8c and 2.2c and/or 3.6c and 4.4c; BerEP4: 
surface and cytoplasmic glycoprotein; 1 Calretinin positive and BerEP4 negative; 2 Calretinin negative 
and BerEP4 positive 
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5 Discussion 
Malignant mesothelioma (MM) is a rare tumor of the serosal membranes with a poor 
prognosis. Predictive studies reported an increased incidence of MM for the next decade 
Hodgson et al. 2005; Price & Ware 2004; Leigh et al. 2002; Peto et al. 1999
. Recent advance in therapy for 
patients with MM can improve the outcome if they are applied to Stage I disease 
Illei et al. 
2003a
. The relationship between asbestos exposure and the development of MM as 
etiologic factor, confirmed by numerous case-control studies, claims compensation from 
workers occupationally exposed to asbestos. An early and precise diagnosis of MM in 
effusion is crucial for patient management and may avoid unnecessary invasive 
diagnostic procedures. Cytology is one of the most specific, time-, and cost-effective 
methods with high clinical relevance. Even cytological diagnosis on serous effusions 
are usually made by routine morphology in certainty, allowing treatment decision, the 
diagnosis of MM is difficult and represents one of the classic diagnostic challenges of 
cytopathology. These difficulties may be overcome by the application of adjuvant 
methods including DNA-image cytometry (DNA-ICM), immunocytochemistry, 
AgNOR-analysis, and chromosomal fluorescence in situ hybridization (FISH). 
 
We investigated the usefulness of cytology, DNA-ICM, immunocytochemistry, 
AgNOR-analysis, and chromosomal FISH for the diagnosis of MM in serous effusion. 
The current study was performed using 33 cases of MM routinely diagnosed between 
March 2005 and May 2007, as described in material and methods and results. To 
compare the utility of the adjuvant methods to identify and type tumor cells in serous 
effusions, we additionally used 31 cases of metastatic carcinomas and 39 cases of tumor 
cell-negative effusions containing reactive mesothelial and applied DNA-image 
cytometry, immunocytochemistry, AgNOR-analysis and FISH in these cases. All cases 
were confirmed by histologic and/or clinical follow up. 
 
DNA-ICM is a standardized quantitative adjuvant method that measures the nuclear 
DNA content by the cytometric equivalent nuclear IOD 
Haroske et al. 2001
. It identifies DNA 
stemlines outside the euploid (diploid, tetraploid, or octaploid) regions as abnormal (or 
aneuploid) at a defined statistical level of significance 
Böcking 1995
. We used two 
algorithms for the identification of DNA-aneuploidy: position of any DNA-stemline and 
occurrence of cells > 9c. Cells between 5c and 8c occur in 6.5% of mesothelial cells in 
5 Discussion 48 
negative effusions 
Biesterfeld et al. 1994
. This is the reason why the threshold for the detecting 
of rare aneuploid had to be set at 9c and not at 5c. 
 
None of the DNA-histograms measured from tumor cell-negative effusions revealed any 
of the mentioned parameters of DNA-aneuploidy in the current study. This result is in 
concordance with the majority of the studies that analyzed DNA-ICM in effusions 
Osterheld et al. 2005, Motherby et al. 2002; Pomjanski et al. 2001; Kayser et al. 2000; Motherby et al. 1999a
. In contrast, 
Palaoro et al. 
2007
 found aneuploid in 3/23 (13%) cases of negative effusions, but they 
did not follow the standards requirements reported by the European Society of 
Analytical Cellular Pathology (ESACP), which probably contributed for these false-
positive results. For this reason, we recommend the strict consideration of the updated 
standards of the ESACP for DNA-ICM 
Haroske et al. 2001; Haroske et al. 1998; Giroud et al. 1998; Böcking et 
al. 1995
 otherwise false-positive and false-negative diagnoses may occur. 
 
In our study, all cases of metastatic carcinomas were found to be DNA-aneuploid. The 
prevalence of aneuploidy in cells from metastatic carcinomas in effusions varies 
between 88.5 and 100% 
Osterheld et al. 2005, Motherby et al. 2002; Pomjanski et al. 2001; Kayser et al. 2000; 
Motherby et al. 1999a
. DNA-aneuploidy was found in 71% of MM cases in the current study. 
This is in agreement with several reports 
Motherby et al. 2002; Kayser et al. 2000
. Pomjanski et al. 
2001
 found DNA-aneuploidy using DNA-ICM in only 52.8% of their MM cases, while 
Osterheld et al. 
2005
 found it in 80%. Aneuploidy seems to represent a consistent marker 
of malignancy; however, euploidy cannot exclude it. Our data confirm the higher 
proportion of euploidy in MMs compared with metastatic carcinomas, which showed 
none euploid cases. In effusions containing malignant cells the location of the greatest 
stemline by DNA-ICM is able to contribute to the differential diagnosis between 
metastatic carcinomas and mesotheliomas 
Motherby et al. 1998a
. While 61.3% of MMs 
showed their greatest stemline within the range of 1.8c and 2.2c and/or 3.6c and 4.4c, 
only 19.4% of metastatic carcinoma showed it in this region. Similar findings were 
reported by Pomjanski et al. 
2001
 and Motherby et al. 
1999a
.  
 
Immunocytochemistry localizes specific antigens in cells and tissues based on antigen-
antibody recognition. In recent years, immunocytochemistry has contributed to the 
differentiation of mesotheliomas from adenocarcinomas
 Li et al. 2006; Ordonez 2006; Ordonez 2003; 
Comin et al. 2001
. As a specific tumor marker for mesotheliomas has not yet been 
recognized, panels of markers are used that frequently are expressed in mesotheliomas 
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(positive mesothelioma marker) combined with those that are commonly expressed in 
adenocarcinomas (negative mesothelioma marker)
 Ordonez 2007
. Calretinin is a 29-
kilodalton (kD) calcium-binding protein that is expressed normally in neurons of the 
central and peripheral nervous system 
Rogers 1987
. BerEP4 is a monoclonal antibody 
directed against a cell surface glycoprotein present in human epithelial cells 
Latza et al. 1990
. 
Calretinin and BerEP4 have been used in panels to differentiate mesotheliomas from 
adenocarcinomas, using calretinin as marker for mesothelial cells and BerEP4 for 
epithelial cells 
Li et al. 2006; Ordonez 2006; Politi et al. 2005; Comin et al. 2001; Pomjanski et al. 2001
.  
 
In the current study, calretinin demonstrated positivity in 100% and BerEP4 in 15.6% of 
MM cases. These results are in concordance to other authors that found similar results 
Ordonez 2006; Comin et al. 2001; Pomjanski et al. 2001
. Li et al. 
2006
 and Politi et al. 
2005
 reported 
calretinin in 100%, but BerEP4 negative in all cases of MM. Our metastatic carcinoma 
cases showed BerEP4 positivity in 87.1% and calretinin in none of them. Some studies 
found calretinin positive in metastatic carcinomas 
Ordonez 2006; Comin et al. 2001; Pomjanski et al. 
2001
. It is suggested that a positive background of benign mesothelial cells could be a 
potential pitfall in the interpretation of calretinin staining patterns 
Li et al. 2006
.  
 
In the cases morphologically suspicious of MM, other immunocytochemical markers 
such as EMA, mesothelin and WT-1 were routinely applied, when more slide existed. 
These markers were not applied in cases of metastatic carcinomas and negative 
effusions because diagnosis could be established with calretinin and BerEP4 alone and 
in most of these cases there was not sufficient material. Usually in MM slides there was 
more number of cells. EMA was performed in 28, mesothelin in 11, and WT-1 in 15 
cases of MM. EMA is an epithelial membrane antigen, a human milk fat globulin, that 
is often expressed by both epithelial mesotheliomas and adenocarcinomas, in 
consequence of it, has little value in differentiating between these tumors 
Comin et al. 2001
. 
EMA demonstrated positivity in 92.9% of MM cases in the current study. Similar 
results were found by other studies 
Comin et al. 2001; Pomjanski et al. 2001
.  
 
Mesothelin is a 40-kDa surface glycoprotein of unknown function that is strongly 
expressed in normal mesothelial cells and mesotheliomas 
Ordonez 2003
. In our study, only 
one from 11 cases of MM was negative for mesothelin. WT-1 suppressor gene is 
suggested to play an important role in the pathogenesis of mesothelioma 
Ordonez 2000
. In 
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2000, Ordonez found 72% positivity of WT-1 in MM, while 93% in 2003 
Ordonez 2003
. 
WT-1 was positive in 66.7% of our MM cases. 
 
AgNOR is a proliferation marker useful in the differential diagnosis of benign and 
malignant cells. The method is applicable with simple light microscopes without 
additional and expensive technical options. However, publications on the use of 
AgNOR methodology in serous effusions are scanty. Unfortunately, it has not yet been 
achieved to a definitive standard for AgNOR staining and quantification and the 
AgNOR scores published for the same tumor types are scarcely comparable 
Trerè 2000
. 
Using a digital image analysis system, Wolanski et al. 
1998
 reported a significant overlap 
in AgNOR counts analyzing nucleoli and AgNOR area per cell. Pomjanski et al. 
2001
 
stated that the total AgNOR counts and satellites were the most efficient method of 
diagnostic AgNOR-analysis to avoid the overlap between reactive and malignant cells 
in effusions. In the current study, we generated receiver-operator characteristic (ROC) 
curves that confirmed those threshold suggested by Pomjanski et al. 
2001
. ROC curves 
demonstrate the coordinate variation in sensitivity and specificity of a test as the 
threshold for defining test positivity varies over the entire range of possible test 
outcomes. Elevating the threshold will improve specificity but will sacrifice sensitivity, 
and vice versa.  
 
Our study showed that malignant cells frequently exhibit a greater AgNOR protein 
amount as compared with corresponding benign cells in concordance with previous 
studies 
Palaoro et al. 2007; Mohanty et al. 2003; Rocher et al. 2000
. The thresholds of ≥ 2.5 AgNOR dots as 
satellites and ≥ 4.5 as total AgNOR counts were found in 89.3% of MM and 96.7% of 
metastatic carcinomas. Only one case of MM showed the AgNOR amount lower than 
this threshold. Three cases were doubtful (two MMs and one metastatic carcinoma of 
the breast), demonstrating that counting of satellites or total AgNOR counts were not 
enough to target the threshold established. We obtained 97.1% corrected diagnoses in 
benign cells in serous effusions. Only one case of tumor cell-negative effusion 
demonstrated an increased number of AgNOR dots (2.5 as satellites and 5.13 as total 
AgNOR counts). The AgNOR-analysis appears to be a sensitive method. Its sensitivity 
is high enough to distinguish benign from malignant cells. The counting procedure had 
no adverse effect on the cutoff value used in the current study. 
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Fluorescence in situ hybridization (FISH) is a powerful molecular technology. Its use 
for diagnostic purposes has increased significantly in the last few years, primarily 
because it provides in situ information about genetic changes and because it can be 
applied to archival and fresh material 
Illei et al. 2003a
. The occurrence of multiple 
cytogenetic deletions in MM suggests that the loss and/or the inactivation of tumor 
suppressor genes (that maintain the normal cell cycle control and genomic integrity in 
the cell) may be critical to the development and progression of this tumor 
Musti et al. 2006; 
Illei et al. 2003b
. The most common cytogenetic abnormality in MM is deletion at 9p21 locus 
within a cluster of genes (CDKN2B, CDKN2A, and MTAP) 
Illei et al. 2003a; Illei et al. 2003b; Hirao 
et al. 2002; Björkqvist et al. 1997; Xiao et al. 1995; Cheng et al. 1994
, which can be used as a marker for 
malignancy in cells from body cavity effusions 
Illei et al. 2003a
. Illei et al. 
2003a
 stated that 
cytologic material is better suited for FISH than sections from paraffin embedded tissue, 
because nuclei are intact, thereby avoiding the problem of nuclear sectioning inherent in 
FISH performed on standard surgical pathology material.  
 
We generated receiver-operator characteristic (ROC) curves to determine the effect of 
various cutoffs, using both homozygous and heterozygous deletion of 9p21 as the 
criterion for positivity due to the relatively low frequency of these events in normal cell 
populations. To avoid over interpretation of incomplete hybridization, the current study 
considered as FISH-positive all specimens containing ≥ 5 nuclei showing homo- or ≥ 15 
nuclei showing heterozygous deletion of 9p21. Illei et al. 
2003a
 used ≥ 15 nuclei as cutoff 
for positive homozygous deletion in cytologic specimens, but it was not explained how 
they obtained this cutoff, and why heterozygous deletion was not used as criteria for a 
FISH-positive result. The 9p21 heterozygous deletion is a criterion used as FISH-
positivity also in other tumor sites, such as bladder cancer in bladder washing samples 
Zellweger et al. 2006
. 
 
The 9p21 homo- and heterozygous deletions were demonstrated in 54.5% and 42.4% of 
MM cases, respectively. This represents 90.9% of 9p21 deletion, when both criteria 
were used. This deletion was reduced in metastatic carcinomas, which showed 19.4% of 
9p21 homozygous deletion, and 32.3% of 9p21 heterozygous deletion. None of the 
negative effusions containing reactive mesothelial cells demonstrated 9p21 deletion, 
100% were FISH negative for this deletion. 
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Previous studies have indicated that the homozygous deletion of 9p21 is present in 
approximately 72-75% of MM patients 
Illei et al. 2003b;
 
Prins et al. 1998; Xiao et al. 1995
 and up to 
100% in mesothelioma cells lines 
Prins et al. 1998; Cheng et al. 1994
. Illei et al. 
2003a
 confirmed a 
diagnosis of MM over reactive mesothelial cell in 12 of 13 patients with positive or 
suspicious cytology. In concordance to the current study, they also reported that all 19 
cytologically negative specimens were negative for 9p21 deletion 
Illei et al. 2003a
. Cheng et 
al. 
1993
 reported homozygous deletion of 9p21-p22 in 43% and homo- and /or 
heterozygous deletion in 83% of MM cell lines. To our knowledge, no study has so far 
reported the 9p21 deletion in metastatic carcinomas by FISH in serous effusions for 
diagnostic purpose. 
 
Cytology plays an important role in the diagnosis of serous effusions. The distinction 
between MM and metastatic carcinoma has always been a diagnostic challenge to both 
clinicians and cytologists. A history of asbestos exposure does not necessary imply a 
diagnosis of MM because patients with such a history also are at risk of developing lung 
carcinoma 
Roach et al. 2002; Hodgson & Darnton 2000
. Furthermore, not all MMs are related to 
asbestos exposure 
Carbone & Bedrossian 2006; Churg et al. 2006; Dogan et al. 2006; Gazdar et al. 2002
. Various 
cytologic features are characteristic of, but not specific for malignant mesothelioma. For 
example, intercellular spaces (windows), commonly observed in cellular aggregates of 
mesothelial cells, also can be identified in 13% of cases of metastatic adenocarcinoma 
Yu et al. 1999
. Due to the dependence of the type of preparation and staining, volume of 
liquid examined, and investigator’s experience, as well as the number of sufficient 
specimens investigated, the reported sensitivity of conventional cytology varies between 
50-84% 
Metgeroth et al. 2007; Osterheld et al. 2005; Motherby et al. 1999c
. A variety of adjuvant methods 
therefore have been applied in order to improve the diagnostic sensitivity and specificity 
in this setting. The sequential use of different adjuvant diagnostic methods can 
contribute to establish a diagnosis in cytologically doubtful and suspicious cases of 
serous effusion. 
 
In the current study, when cytology was used alone for the diagnosis of MM, 81.8% of 
cases were reported with certainty as tumor cell positive, confirmed by histologic and/or 
clinical follow-up. The addition of DNA-ICM improved the prevalence of positivity to 
87.9% and the addition of AgNOR to 97% as shown in tables 11 and 12. The 
introduction of FISH as adjuvant method could improve the prevalence of tumor cell-
detection to 100% if 9p21 homo- and heterozygous deletion were used as diagnostic 
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parameters. Our results confirm data from literature suggesting a diagnostic impact of 
DNA-ICM and AgNOR to a MM diagnosis as reliable adjuvant methods 
Pomjanski et al. 2001; 
Motherby et al. 1999a; Motherby et al. 1999b
. When a suspicious towards the presence of malignant 
mesothelioma cells is raised in a serous effusion, but the above mentioned methods are 
not sufficient to establish a definitive diagnosis, we suggest the application of FISH to 
detect 9p21 deletions especially when dealing with limited amount of cellular material. 
 
To differentiate metastatic carcinoma from MM or reactive mesothelial cells, 
immunocytochemistry has proven to be the most useful method. It is generally agreed 
that no single antibody is sufficiently sensitive or specific. In our study, we concluded 
that the application of calretinin and BerEP4 has an excellent detection rate for 
malignant cells. Calretinin-positivity was found in all cases of MM and negativity in all 
cases of metastatic carcinoma. BerEP4-positivity was found in 15.6% of MM, 87.1% of 
metastatic carcinoma and 0% of negative effusions. The combination of calretinin-
positivity and BerEP4 negativity was found in 84.4% of MM cases. The addition of the 
DNA-polyploidy parameter increased the prevalence to 90.6%. The location of the 
greatest stemline by DNA-ICM in effusions containing malignant cells was able to 
contribute to differential diagnosis between metastatic carcinomas and MMs. As such 
9p21 homozygous deletion was applied; all cases of MM could be corrected diagnosed. 
The high prevalence of 9p21 deletion in MM can also be used as a diagnostic marker to 
distinguish reactive from neoplastic mesothelial cells in effusions. 
 
Based on our results, we established an algorithm for the application of adjuvant 
methods in routine cytological smears to identify and type tumor cells in serous 
effusions (Figure 43). In the group of patients with finally tumor cells positive effusions 
in which this algorithm can not unequivocally differentiate between MM and metastatic 
carcinoma, there is a necessity for further investigations. To establish a definitive 
diagnosis, pleural or peritoneal biopsy should be performed.  
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Figure 43: Flow chart for the application of adjuvant methods in routine cytological smears to identify 
and type tumor cells in serous effusions. DNA-ICM: DNA-image cytometry; AgNOR: silver staining of 
nucleolar organizer regions-associated protein; BerEP4: surface and cytoplasmic glycoprotein; FISH: 
fluorescence in situ hybridization. 
 
 
In conclusion, we have shown that many cases in which cytology on serous effusions is 
suspicious or doubtful can definitely be solved by one of these methods or by their 
combination and that these may be performed on existing cytological routine smears. 
The documented low sensitivity of conventional cytology to identify malignant 
mesothelioma cells in effusions indicates the necessity of applying adjuvant diagnostic 
methods in order to improve diagnostic accuracy. All these different diagnostic methods 
bear individual intrinsic advantages and disadvantages in terms of specificity and 
sensitivity, laborious effort, and cost effectiveness. We tried to develop a reasonable 
combination of markers to improve the diagnostic accuracy of malignant mesothelioma 
detection in serous effusions. Further studies on larger series of patients are needed to 
evaluate the validity and efficiency of this approach for improving the diagnostic 
accuracy of effusion cytology. 
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BACKGROUND: Malignant mesothelioma (MM) is a rare tumor of the serosal 
membranes with a poor prognosis. Studies predict an increasing incidence of this tumor 
in the next decade. An early and precise diagnosis of MMs in effusions is crucial for 
patient management and may avoid unnecessary invasive procedures. However, this 
diagnosis represents one of the classic diagnostic challenges of cytopathology in serous 
effusions. It may be overcome by the application of adjuvant methods. The current 
study investigated the usefulness of cytology, DNA-image cytometry (DNA-ICM), 
immunocytochemistry, AgNOR-analysis, and chromosomal fluorescence in situ 
hybridization (FISH) for the diagnosis of MM and of metastatic carcinoma in serous 
effusion. 
 
MATERIALS AND METHODS: A total of 33 effusions received between March 2005 
and May 2007 were cytologically diagnosed as suspicious or positive for MM cells 
using DNA-ICM, immunocytochemistry and AgNOR-analysis as adjuvant methods. 
We further investigated the detection of 9p21 deletions by chromosomal FISH. To test 
the utility of adjuvant methods to identify and type tumor cells in serous effusions, we 
investigated additionally 31 cases of metastatic carcinomas and 39 of tumor cell-
negative effusions containing reactive mesothelial cells only, applying DNA-ICM, 
immunocytochemistry, AgNOR-analysis and chromosomal FISH. All diagnoses were 
confirmed by histologic and/or clinical follow up. 
 
RESULTS: Using DNA-ICM, aneuploidy was found in 71% of MMs, 100% of 
metastatic carcinomas and in none of tumor cell-negative effusions. 61.3% of MMs 
showed their greatest DNA stemline within the range of 1.8c and 2.2c and/or 3.6c and 
4.4c, while only 19.4% of metastatic carcinomas showed their greatest stemline in this 
region. The immunocytochemical marker Calretinin was positive in 100% of MMs, 
none of metastatic carcinomas and 94.9% of reactive mesothelial cells in tumor cell-
negative effusions. BerEP4 showed positivity in 15.6% of MMs, 87.1% of metastatic 
carcinomas and none of tumor cell-negative effusions. Using AgNOR-analysis, 89.3% 
of MMs, and 96.7% of metastatic carcinoma showed ≥ 2.5 AgNOR dots as satellites 
and ≥ 4.5 as total AgNOR counts. Only one case of tumor cell-negative effusion 
revealed an increased number of AgNOR dots. 9p21 homo- and heterozygous deletions 
were demonstrated in 54.5% and 42.4% of MM cases, respectively. This represents 
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90.9% of 9p21 deletion, when both criteria are applied. In metastatic carcinomas, the 
9p21 homozygous deletion was found in 19.4% and in 32.3% a 9p21 heterozygous 
deletion. None of the tumor cell-negative effusions demonstrated 9p21 deletions. When 
cytology alone was used for the diagnosis, 81.8% of MM cases were identified with 
certainty as tumor cell positive, confirmed by histologic and/or clinical follow-up. The 
addition of DNA-ICM improved the prevalence of tumor cell detection to 87.9% and 
the addition of AgNOR-analysis to 97%. The further introduction of FISH as an 
adjuvant method could improve the prevalence of tumor cell-detection to 100% if 9p21 
homo- and heterozygous deletion were used as diagnostic parameters. To differentiate 
metastatic carcinoma from MM or reactive mesothelial cells, calretinin positivity was 
found in all cases of MM and in none of metastatic carcinoma; BerEP4 positivity was 
found in 15.6% of MM, 87.1% of metastatic carcinoma and none of tumor cell- 
negative effusions. The combination of calretinin positivity and BerEP4 negativity was 
found in 84.4% of MM cases. 
 
CONCLUSION: We have shown that many cases in which cytology on serous effusions 
is suspicious or doubtful can definitely be solved by one of these adjuvant methods or 
by their combination and that these may be performed on existing routine cytological 
smears. The diagnostic methods used in the current study bear individual intrinsic 
advantages and disadvantages in terms of specificity and sensitivity, laborious effort, 
and cost effectiveness. Based on our results, we suggest first the parallel application of 
DNA-ICM, immunocytochemistry, and AgNOR-analysis as adjuvant methods to solve 
difficult cases of diagnostic cytology in serous effusion. Persistent doubtful diagnoses 
could be overcome by the application of FISH to analyze the 9p21 deletion. Further 
studies on larger series of patients are needed to evaluate the validity and efficiency of 
this approach to improve the diagnostic accuracy of effusion cytology. 
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HINTERGRUND: Das Maligne Mesotheliom (MM) ist ein seltener Tumor der serösen 
Häute mit schlechter Prognose. Prädiktive Studien berichteten über einen Anstieg der 
Inzidenz dieses Tumors in der folgenden Dekade. Eine frühe und präzise zytologische 
Diagnose des MM in Körperhöhlen-Ergüssen ist für das folgende therapeutische 
Procedere essentiell und kann invasive Diagnoseverfahren vermeiden helfen. Die 
Diagnose des MM in Körperhöhlen-Ergüssen stellt eine der klassischen diagnostischen 
Herausforderungen der Zytopathologie dar, wird aber in Zukunft stark durch die 
Verwendung von adjuvanten Methoden unterstützt. Die vorliegende Arbeit untersucht 
den diagnostischen Nutzen der Zytologie, DNA-Bildzytometrie, Immunzytochemie, 
AgNOR-Analyse und der chromosomalen Fluoreszenz in-situ Hybridisierung (FISH) 
für die Diagnose des MM in serösen Ergüssen im Vergleich zu metastatischen 
Karzinosen. 
 
MATERIAL UND METHODEN: 33 Körperhöhlenergüsse, die zwischen März 2005 
und Mai der 2007 im Institut für Cytopathologie untersucht wurden, wurden zytologisch 
als positiv oder verdächtig auf das Vorliegen von Zellen, eines MM diagnostiziert. Dies 
geschah unter adjuvantem Einsatz von DNA-Bildzytometrie, Immunzytochemie und 
AgNOR-Analyse. Zusätzlich bestimmten wir den diagnostischen Nutzen einer 
möglichen 9p21 Deletion mittels chromosomalen FISH. Zum Vergleich der 
diagnostischen Möglichkeiten verschiedene adjuvante Methoden (DNA-Bildzytometrie, 
Immunzytochemie, AgNOR-Analyse und FISH) zur Identifizierung und Typisierung 
von Tumor Zellen, haben wir zusätzlich 31 Ergüsse mit metastatischen Zellen und 39 
Tumorzell-negative Ergüsse untersucht. Die Diagnosen aller diese Fälle wurden mittels 
histologischem und/oder klinischem Follow-up validiert. 
 
ERGEBNISSE: Die DNA-Bildzytometrie zeigte Aneuploidie bei 71% der MM, bei 
100% von metastatischen Karzinomen und nie bei Tumorzell-negativen Ergüssen. 
61.3% der MM zeigten ihre größten DNA-Stammlinien innerhalb des Bereiches 1.8c bis 
2.2c und/oder 3.6c bis 4.4c, während nur 19.4% der metastatischen Karzinome ihre 
größte Stammlinie in dieser Region zeigten. Der immunzytochemische Marker 
Calretinin war positiv bei 100% der MM, bei keiner der metastatischen Karzinome und 
bei 94.9% der reaktiven Mesothelzell-reichen, Tumorzell-negativen Ergüsse. Der 
immunzytochemische Marker BerEP4 war positiv bei 15.6% der MM, 87.1% der 
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metastatischen Karzinome und keiner der Tumorzell-negativen Ergüssen. Mittels 
AgNOR-Analyse zeigten 89.3% der MM und 96.7% der metastatischen Karzinosen ≥ 
2.5 Satelliten und ≥ 4.5 gesamte AgNORs pro Zellkern. Bei nur einem Patienten mit 
Tumorzell-negativem Erguss zeigte sich eine erhöhte Anzahl von AgNORs. Homo- und 
heterozygote Deletionen von 9p21 traten bei 54.5% beziehungsweise 42.4% der MM 
auf. Unter Verwendung beider Kriterien zeigte sich eine 9p21 Deletion bei 90.9% der 
MM. Bei Karzinommetastasen wurde eine homozygote 9p21 Deletion in 19.4% und 
eine heterozygote 9p21 Deletion in 32.3% gefunden. Keiner der Tumorzell-negativen 
Ergüsse zeigte einen 9p21 Deletion. Mittels Zytomorphologie alleine wurden 81,8% der 
MM als sicher positiv diagnostiziert, was durch histologisches und/oder klinisches 
Follow-up bestätigt wurde. Die Hinzunahme der DNA-Bildzytometrie verbesserte die 
Prävalenz auf 87.9% und die Hinzunahme der AgNOR-Analyse auf 97%. Wenn 
zusätzlich das Vorliegen einer homo- oder heterozygoten Deletion von 9p21 mittels 
FISH bestimmt wird, wurde die Prävalenz eines Tumorzell-Nachweises auf 100% 
gesteigert. Calretinin positive Zellen wurden bei allen MM und bei keinem 
metastatischen Karzinom, BerEP4 positive Zellen bei 15.6% der MM, bei 87.1% der 
Karzinommetastasen und bei keinem Tumorzell-negativen Erguss gefunden. Die 
Kombination Calretinin-positiv und BerEP4-negativ zeigten 84.4% der MM. 
 
SCHLUSSFOLGERUNGEN: Es konnte gezeigt werden, dass viele zytologisch nicht 
eindeutige Verdachtsfälle auf ein MM durch Anwendung der vorgenannten adjuvanten 
Methoden alleine oder in Kombination gelöst werden können. Diese können an den 
bereits existierenden zytologischen Routinepräparaten durchgeführt werden. Die in 
dieser Arbeit verwendeten Diagnosemethoden haben jeweils eigene Vor- oder Nachteile 
bezüglich der Spezifität, der Sensitivität, des Arbeitsaufwandes sowie der Kosten. 
Deshalb wird auf der Grundlage der hier vorgelegten Ergebnisse vorgeschlagen, bei 
Zytodiagnostisch unsicheren Fällen seröser Körperhöhlenergüsse zusätzlich zur 
Zytologie erst die DNA-Bildzytometrie, die Immunzytochemie und die AgNOR 
Analyse als adjuvante Methoden zu verwenden. Weiter unklar bleibende Fälle sollten 
zusätzlich auf das Vorliegen einer 9p21 Deletion mittels FISH untersucht werden. 
Weitere Untersuchungen mit größeren Patientenzahlen sind erforderlich, um Validität 
und Effizienz des vorgeschlagenen diagnostischen Vorgehens zur Verbesserung der 
diagnostischen Sicherheit in der Ergusszytologie zu bestimmen. 
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